Data-driven learning how oncogenic gene expression locally alters heterocellular networks

David J. Klinke II^{1-3 \boxtimes}, Audry Fernandez^{2,3}, Wentao Deng^{2,3}, and Anika C. Pirkey¹

¹Department of Chemical and Biomedical Engineering, West Virginia University, Morgantown, WV
²Department of Microbiology, Immunology and Cell Biology, West Virginia University, Morgantown, WV
³WVU Cancer Institute, West Virginia University, Morgantown, WV

Discovering and developing pharmaceutical drugs increas-1 ingly relies on mechanistic mathematical modeling and simu-2 lation. In immuno-oncology, models that capture causal rela-3 tions among genetic drivers of oncogenesis, functional plasticity, and host immunity provide an important complement to wet 5 experiments, given the cellular complexity and dynamics within 6 the tumor microenvironment. Unfortunately, formulating such 7 mechanistic cell-level models currently relies on hand curation 8 by experts, which can bias how data is interpreted or the priq ority of drug targets. In modeling molecular-level networks, 10 rules and algorithms have been developed to limit a priori bi-11 ases in formulating mechanistic models. To realize an equivalent 12 approach for cell-level networks, we combined digital cytome-13 try with Bayesian network inference to generate causal models 14 that link an increase in gene expression associated with onco-15 genesis with alterations in stromal and immune cell subsets di-16 17 rectly from bulk transcriptomic datasets. To illustrate, we predicted how an increase in expression of Cell Communication 18 Network factor 4 (CCN4/WISP1) altered the tumor microenvi-19 ronment using data from patients diagnosed with breast cancer 20 and melanoma. Network predictions were then tested using two 21 immunocompetent mouse models for melanoma. In contrast to 22 hand-curated approaches, we posit that combining digital cy-23 tometry with Bayesian network inference provides a less biased 24 approach for elaborating mechanistic cell-level models directly 25 from data. 26

Heterocellular networks | digital cytometry | deconvolution | anti-tumor
 immunity | Bayesian network inference | functional plasticity

29 Correspondence: *david.klinke@mail.wvu.edu*

30 Introduction

Tissues are dynamic structures where different cell types or-31 ganize to maintain function in a changing environment. For 32 instance, the mammary epithelium reorganizes during dis-33 tinct stages of the ovarian cycle in preparation for lactation 34 (Klinke, 2016). At the same time, immune cells clear dead 35 cells and defend against pathogens present in the tissue mi-36 croenvironment. Ultimately, the number and functional ori-37 entation of different cell types within a tissue interact to cre-38 ate a network, that is a heterocellular network. This hetero-39 cellular network is essential for creating and maintaining tis-40 sue homeostasis. While we know that tissue homeostasis is 41 disrupted during oncogenesis, our understanding of how ge-42 netic alterations quantitatively and dynamically influence the 43 heterocellular network within malignant tissues in humans 44

is not well developed despite large efforts, like The Cancer
Genome Atlas (TCGA), to characterize the genomic and transcriptomic landscape in human malignancy (Hoadley et al., 2018; Wells and Wiley, 2018). In parallel with these large
scale data gathering efforts, two informatic developments, namely digital cytometry and Bayesian network inference, may be helpful in interrogating these datasets.

In cytometry, single-cell sequencing technology elicits a 52 lot of excitement as it enables unbiased discovery of novel 53 cell subsets in particular disease states (Papalexi and Satija, 54 2018; Singer and Anderson, 2019). Unfortunately, per-55 sistent challenges related to confounding of batch effects 56 with biological replicates limit the statistical power of these 57 datasets to link oncogenic transcriptional changes with re-58 organization of the cellular network (Grun et al., 2014; Stuart 59 and Satija, 2019). Due to the high number of biological repli-60 cates, transcriptomic datasets, such as the Cancer Genome 61 Atlas, provide a rich resource in characterizing the hetero-62 geneity of oncogenic transformation. Yet, these data were 63 obtained from homogenized tissue samples and reflect the ex-64 pression of genes averaged across a heterogeneous cell pop-65 ulation. Computationally, "Digital Cytometry" can deconvo-66 lute the prevalence of individual cell types present within a 67 mixed cell population (Newman et al., 2019). The approach 68 stems from the idea that the influx of a particular cell subset 69 into a tissue corresponds to an increase in a gene signature 70 uniquely associated with this particular cell subset (Shen-Orr 71 et al., 2012; Yoshihara et al., 2013; Wang et al., 2018; Zait-72 sev et al., 2019). Gene signatures of immune cells have been 73 developed in a number of studies, which increasingly lever-74 age scRNAseq data and machine-learning methods (Shen-75 Orr et al., 2010; Becht et al., 2016; Schelker et al., 2017; 76 Torang et al., 2019). Besides representing different cellu-77 lar subsets, gene signatures can also represent intracellular 78 processes associated with oncogenesis, like the epithelial-79 mesenchymal transition (Tan et al., 2014; Koplev et al., 2018; 80 Malta et al., 2018; George et al., 2017; Klinke and Torang, 81 2020). Though, the predictive value of many of these tis-82 sue "features" in inferring how heterocellular networks are 83 altered in diseased tissues remain unclear, as establishing cor-84 relations among features tends to be the end point of studies 85 (e.g., (Tosolini et al., 2011; Malta et al., 2018; Thorsson et al., 86 2018)). 87

Increases in size and information content of transcrip-

tomic datasets enable using probabilistic inference methods 89 to identify relationships within the data that could not be ob-90 served using simpler statistical techniques (Hill et al., 2016; 91 Friedman, 2004). However to infer how heterocellular net-92 works are altered in diseased tissues, we need to be able 93 to identify the direction of information flow within the net-94 work, that is the causal relationships among interacting com-95 ponents. One method to identify the topology of a causal 96 network in an unbiased way is to use algorithms that identify 97 Bayesian networks (Scutari, 2010). Bayesian networks are a 98 type of directed acyclic graphs (DAG), where each node rep-99 resents a random variable, or "feature", and each edge rep-100 resents a causal relationship between two nodes. As algo-101 rithms for reconstructing Bayesian networks emerged, they 102 were used to model signaling pathways within cells (Sachs 103 et al., 2002), to identify known DNA repair networks in E. 104 coli using microarray data (Perrin et al., 2003) and to iden-105 tify simple phosphorylation cascades in T lymphocytes using 106 flow cytometry data (Sachs et al., 2005, 2009). While many 107 more studies have been published since, a common conclu-108 sion is that the statistical confidence associated with an in-109 ferred network improves as the number of samples included 110 in a dataset is greater than the number of random variables. 111 However, transcriptomics data, like that obtained as part of 112 the TCGA, typically have a large number of random vari-113 ables (n_{genes}) and a small number of biological replicates 114 $(n_{patients})$, which makes inferring gene-level networks com-115 putationally difficult (Zou and Conzen, 2005). 116

As summarized in Figure 1, we propose an approach that 117 combines digital cytometry with Bayesian network infer-118 ence to identify how heterocellular networks associated with 119 functional plasticity and anti-tumor immunity change during 120 oncogenesis in humans. Conceptually, digital cytometry im-121 proves the statistical power by projecting the transcriptomic 122 space onto a smaller number of "features" that estimate the 123 prevalence of stromal and immune cell types and the average 124 differentiation state of malignant cells present within the tu-125 mor microenvironment, such that $n_{features} \ll n_{patients}$. 126 The causal structure among these features can then be pre-127 dicted using Bayesian network inference. While data un-128 structured in time, such as the TCGA datasets, are not ideal 129 for inferring causality, we test the inferred networks using in 130 vivo experiments using syngeneic murine tumor models. 131

To illustrate the approach, we focused on Cell Communi-132 cation Network factor 4 (CCN4/WISP1), as it is upregulated 133 in invasive breast cancer (Klinke, 2014) and correlates with 134 a lower overall survival in patients diagnosed with primary 135 melanoma (Deng et al., 2019). Functionally, CCN4 promotes 136 metastasis in melanoma by promoting a process similar to the 137 epithelial-mesenchymal transition (Deng et al., 2019, 2020). 138 In developing state metrics that quantify functional plastic-139 ity in breast cancer and melanoma using an unsupervised ap-140 proach, CCN4 was the only gene associated with both a mes-141 enchymal state metric in breast cancer and a de-differentiated 142 state metric in melanoma that results in a secreted protein 143 (Klinke and Torang, 2020). The collective set of features, 144 or simply nodes of a network, were quantified in three tran-145

scriptomic datasets obtained from bulk tissue samples from patients with breast cancer and melanoma and used to generate a casual network describing how expression of a "gene driver" associated with oncogenesis, such as CCN4, alters the heterocellular network within a tissue using Bayesian network inference.

152

Results

Generating causal graphs that link oncogenic 153 changes in gene expression with changes in the het-154 erocellular network. Bayesian network inference involves 155 inferring the structure of the network, which captures the 156 specific interactions or edges among the nodes of a network 157 and represents them as a directed acyclic graph (DAG), and 158 then estimating the parameters of the conditional probability 159 distribution from the datasets. We used a two-step process to 160 learn the causal structure associated the cell-level networks. 161 First, we created a collection of edges that were consistently 162 identified among the different structural learning algorithms. 163 that is a consensus seed network. In the initial structure 164 learning step, an overall flow of the network was specified 165 by limiting the inclusion of edges into a proposed network. 166 In particular, we considered only edges into the "CD8 T 167 cells" node (i.e., a leaf node), only edges that originate 168 from the "Cancer" node (i.e., a root node), mostly edges 169 that originate from the "CCN4" node (with exception for 170 the "Cancer" node), and only edges into the "CD4 T cells" 171 and "Neutrophils" nodes. Specifying "CD4 T cells" and 172 "Neutrophils" as leaf nodes follows from the high number of 173 zero values for those features in the dataset, which were 350 174 and 439 samples in the BRCA dataset, respectively. This 175 was implemented by assigning the corresponding edges to a 176 "blacklist". Collectively, this represents a way to incorporate 177 prior knowledge about causal relationships associated with 178 oncogenesis and the roles that specific immune cells play in 179 controlling tumor cell growth. 180

As algorithms for structural learning have different under-181 lying assumptions, we used an ensemble approach to average 182 across the different algorithms to identify an initial structure 183 of the DAG. Specifically, we used nine different structural 184 learning algorithms (Scutari, 2010), including a pairwise mu-185 tual information (ARACNE), constraint-based (Incremental 186 association Markov Blanket - IAMB, Incremental associa-187 tion with false discovery rate control - IAMB.FDR, practi-188 cal constraint - PC.STABLE), local discovery of undirected 189 graphs (max-min parents and children - MMPC, Hiton par-190 ents and children - SI.HITON.PC), score-based (hill climbing 191 - HC, Tabu search - Tabu), and hybrid learning (max-min hill-192 climbing - MMHC) algorithms. Bootstrap resampling was 193 used in learning the network structure with each algorithm, 194 which resulted in generating 10,000 network structures. For 195 each algorithm, an averaged network structure was calculated 196 from the collection of network structures, where the thresh-197 old for inclusion of a edge into the average network was 198 automatically determined by each algorithm and was nom-199 inally 0.5. Whether a particular edge promotes or inhibits 200 the target node was determined based on the sign of the cor-201

relation coefficient between the two nodes. We applied the 202 same approach to both the breast cancer (BRCA - Figures 2 203 and 3) and the two melanoma datasets (common melanocytic 204 nevi and primary melanoma: GEO and primary melanoma 205 from the TCGA: SKCM - Figures S4 and 5). To generate 206 consensus seed networks, the BRCA dataset was analyzed 207 alone (see Table S1) while results for the two melanoma 208 datasets (see Tables S2 (GEO) and S3 (SKCM)) were used 209 together. Including edges in the consensus seed network 210 was based on consistency among algorithms, strength of the 211 edge, and whether the edge provided a new connection link-212 ing the "Cancer" node with effector immune cell nodes, such 213 as "CD4 T cells" or "CD8 T cells", or potential negative feed-214 back mechanisms, which is illustrated graphically in Figures 215 2 and S4. For instance, in analyzing the BRCA dataset, edge 216 numbers 32 ("Cancer" \rightarrow "pM1"), 37 ("Cancer" \rightarrow "B cells 217 naive"), 45 ("CCN4" \rightarrow "Macrophages"), 46 ("Cancer" \rightarrow 218 "resting NK cells"), and 53 ("CCN4" \rightarrow "active NK cells") 219 were included as they provided novel edges to the consen-220 sus seed network. The inferred direction of a number of 221 edges varied among the algorithms (yellow bars in Figures 222 2 and S4) and were left out of the consensus seed network. 223 The final network for each dataset was generated using a 224 hybrid learning algorithm (mmhc) using a "blacklist" spec-225 ified based on prior causal knowledge and a "whitelist" cor-226 responding to the consensus seed network. Similar to the first 227 step, bootstrap resampling ($n_{boot} = 10,000$) and network av-228 eraging were used to generate the DAGs shown in Figures 3 229 and 5. The averaged DAG was used to generate parameters 230 for a linear Gaussian model estimated by maximum likeli-231 hood and conditioned on the network structure that approx-232 imates the joint probability distribution associated with the 233 dataset. Values for the linear coefficients and the average 234 node values were used to annotate the DAGs. 235

Oncogenesis in breast cancer was associated with a shift 236 from epithelial to mesenchymal cell state accompanied by 237 an increase in cell proliferation and a suppression of en-238 dothelial cells, which were inferred with high confidence. In 239 turn, endothelial cells promote the infiltration of CD4 T cells. 240 The local structure associated with "Cancer"'s influence on 241 the "Mesenchymal" state via "CCN4" suggests an incoherent 242 type-3 feed-forward motif to regulate the mesenchymal state, 243 with CCN4 also inhibiting active NK cells. The high confi-244 dence edge between active NK and resting NK cells follows 245 from these features being mutually exclusive in the dataset 246 and very few samples having zero values for both features. 247 The mesenchymal state increased cancer-associated fibrob-248 lasts ("s) with high confidence. Interestingly, oncogenesis 249 was also associated with increasing the prevalence of a type 1 250 macrophage, which in turn promoted the recruitment of CD8 251 T cells. The prevalence of CD8 T cells are also connected to 252 "Cancer" via a larger incoherent feed-forward motif involv-253 ing "CCN4" and "CAFs" with high confidence. 254

As there was more data supporting the BRCA DAG, the resulting Bayesian network model was compared against the underlying experimental data and used to explore the impact of varying CCN4 expression in the context of normal and tumor tissue (Figure 4). To simulate "normal" and "tumor" 259 tissue, we queried the conditional probability distribution by 260 generating samples from the Bayesian network and filtered 261 the values based on p("Cancer" < 0.15) and p("Cancer" >262 0.85), which are colored in orange and blue, respectively. 263 Corresponding experimental data points and trendlines are 264 overlaid upon the posterior distributions. The posterior dis-265 tributions mirror the experimental data points, where there is 266 an increase in CCN4 expression between "normal" and "tu-267 mor" tissue. The posterior distributions mirror the variability 268 observed in the experimental data when comprised of non-269 zero values, such as CD8 T cells. In contrast, the prevalence 270 of zero values increased the range of the posterior distribu-271 tion, such as for CD4 T cells. In comparing "normal" to 272 "tumor" tissue, CD8 T cells was the only feature, on aver-273 age, increased in "tumor" tissue, while CD4 T cells, B cells, 274 and cancer associated fibroblasts were decreased. Slopes 275 of the trendlines highlight the influence of CCN4 gene ex-276 pression on the prevalence of different immune cell popula-277 tions. Increased CCN4 had the most pronounced inhibition 278 on NK cells and also suppressed CD8 T cells. CCN4 also had 279 a pronounced positive impact on the prevalence of cancer-280 associated fibroblasts, macrophages, and slightly promoted 281 CD4 T cells. CCN4 seemed to have little to no impact on 282 B cells in "normal" tissue while inhibited B cells in "tumor" 283 tissue. 284

The breast cancer dataset contained 582 samples, of which 285 8.8% were from normal mammary tissue. In contrast, the 286 two melanoma datasets contained 78 GEO samples, which 287 includes 34.6% benign nevi, and 94 SKCM samples of pri-288 mary melanoma only. While a lower number of samples 289 limits the inferential power of a dataset, we decided not to 290 combine them together as they had different distributions in 291 transcript abundance as a function of transcript length. As 292 the Bayesian network inference algorithm leverages differ-293 ences in the magnitude of a feature within a population, ap-294 proaches to harmonize these two datasets may introduce a 295 systemic bias that is convoluted with oncogenic transforma-296 tion, as the GEO dataset has many samples obtained from be-297 nign nevi while the SKCM dataset does not. We decided to 298 analyze the melanoma datasets separately and combine the 299 enriched edges in each dataset into a consensus seed net-300 work that reflects both datasets. In analyzing the melanoma 301 datasets, edge numbers 26 ("CAF" \rightarrow "CD8 T cells") and 302 30 ("CCN4" \rightarrow "CAF") in the GEO analysis while edge 303 numbers 17 ("CCN4" \rightarrow "CAF"), 18 ("CAF" \rightarrow "CD8 T 304 cells"), and 22 ("Active NK cells" \rightarrow "CD8 T cells") from 305 the SKCM analysis were included in the consensus seed net-306 work. This consensus seed network was then included in the 307 "whitelist" to learn the structure and parameters associated 308 with Bayesian network inferred from the melanoma datasets 309 (see Figure 5). 310

Given the high prevalence of samples from benign nevi in the GEO dataset, high confidence edges in the GEO network focus on changes associated with oncogenesis. Similar to the breast cancer analysis, oncogenesis was associated with a shift from an epithelial to a mesenchymal-like cell state and 312

the promotion of cell proliferation. Here, the mesenchymal 316 cell state is promoted by both oncogenesis and CCN4 with 317 a coherent feed-forward motif. Similar to the breast cancer 318 analysis, oncogenesis promoted an increase in CD8 T cells, 319 but indirectly by recruiting active NK cells. In contrast to 320 the breast cancer analysis, CCN4 directly impacted CAFs 321 and resting NK cells, although the "CCN4" \rightarrow "resting NK 322 cells" edge had both low confidence and low influence pa-323 rameter. In analyzing the SKCM dataset, less emphasis is 324 placed on the changes associated with oncogenesis but how 325 expression of CCN4 influenced the network. Similarly to the 326 GEO analysis, the SKCM dataset suggested that CCN4 di-327 rectly impacted the mesenchymal state, CAFs, and resting 328 NK cells, but the influence on resting NK cells changed from 329 a slight inhibition in the GEO dataset (-0.11) to strong pro-330 motion in the SKCM dataset (0.75). In addition, the edge 331 between CAFs and the mesenchymal state was inferred with 332 high confidence but changing direction between GEO and 333 SKCM datasets suggests that the algorithms were unable to 334 discern edge direction from the data. In both melanoma 335 datasets, CAFs influence CD8 T cells via an incoherent feed-336 forward motif involving the prevalence of macrophages. In 337 addition, Neutrophils, macrophage polarization, and B cells 338 were independent of oncogenesis and CCN4 expression. In 339 all three analysis, there was high confidence associated with 340 the edges among the nodes quantifying macrophage polariza-341 tion, which is likely an artifact of formula used to calculate 342 $p(M\Phi i)$'s. Queries of the conditional probability distribu-343 tion based on the SKCM DAG for CD8 T cells, active NK 344 cells, Macrophages, B cells, and CAFs were similar to the 345 BRCA analysis (Fig. S5). Similar to the BRCA analysis, a 346 high number of zero values for the CD4 T cell features in the 347 SKCM dataset suggests caution in interpreting differences in 348 CD4 T cell predictions. 349

Validating the impact of CCN4 on heterocellular net-350 works using syngeneic mouse models. Syngeneic im-351 munocompetent mouse models of cancer provide an impor-352 tant complement to retrospective studies of human data as 353 they can aid in causally linking genetic alterations with cel-354 lular changes the tumor microenvironment. Here we used 355 two syngeneic transplantable models for melanoma to test 356 the predictions generated by the Bayesian network inference: 357 the spontaneous B16F0 model and the YUMM1.7 model that 358 displays Braf^{V600E/WT} Pten^{-/-} Cdkn2^{-/-} genotype. As 359 these cell lines basally produce CCN4, we generated CCN4 360 knock-out (KO) variants of these parental cell lines using a 361 CRISPR/Cas9 approach and confirmed CCN4 KO by testing 362 conditioned media for CCN4 by ELISA. Tumors were gener-363 ated by injecting the cell variants subcutaneously in 6-8 week 364 old female C57BL/6 mice and monitoring for tumor growth 365 (n = 5 in each group). Once wt tumors reached between 1000 366 and 1500 mm³ in size, tumors were surgically removed from 367 all mice that were not considered outliers and processed into 368 single cell suspensions (n = 3 for YUMM1.7 variants and n 369 = 4 for B16F0 variants). The single cell suspensions were 370 aliquoted among three antibody panels to characterize the 371 tumor infiltrating lymphocytes by flow cytometry (see Sup-372

plementary Figures S8-S10 for gating strategies). While the B16F0 and YUMM1.7 KO variants were generated using a double nickase CRISPR/Cas9 approach, similar results were obtained using a homology directed repair strategy (Fernandez et al., 2020; Deng et al., 2020). 377

The percentage of CD45⁺ cells among total live cells ex-378 hibited a semi-log dependence on tumor size (Fig. 6A -379 B16F0: $R^2 = 0.607$, F-test p-value = 7.27E-6; YUMM1.7: 380 $R^2 = 0.830$, F-test p-value = 1.48E-7), where CCN4 KO 381 resulted in smaller tumors in both cell models with greater 382 $CD45^+$ cell infiltration. As illustrated in Figure 6A, 383 YUMM1.7 variants had a much higher dependence on tumor 384 size than B16F0 variants. Conventionally, flow cytometry 385 data are normalized to tumor size to estimate the prevalence 386 of a particular cell type per tumor volume. Yet, the depen-387 dence on tumor size could be a confounding factor in addi-388 tion to CCN4 expression that could skew the results. More-389 over, the Bayesian network analysis predicts the impact of 390 CCN4 alone on the prevalence of specific immune cell sub-391 sets. Thus, we focused instead on the prevalence of a par-392 ticular cell type within the live CD45⁺ TIL compartment to 393 compare against the Bayesian network predictions. 394

In comparing the wt B16F0 and YUMM1.7 models, the 395 relative prevalence of NK, CD4⁺ T, and CD8⁺ T cells were 396 similar while B cells were almost 10-times more prevalent in 397 the B16F0 tumors compared to YUMM1.7 tumors (Fig. 6B). 398 The prevalence of these different cell types changed within 399 the CD45⁺ TIL compartment upon CCN4 KO (Fig. 6C and 400 D). Figure 6C highlights the trends among the mouse models 401 and compares against the Bayesian network predictions ob-402 tained from the BRCA and SKCM datasets. Predictions for 403 the change in cell type prevalence by CCN4 expression were 404 obtained by propagating a change in the "CCN4" node from 405 0 to 1 within the linear Gaussian model to the target node, 406 which is also represented by the slope of the "Cancer" trend-407 lines in Figures 4 and S5. Specifically, CD4 and CD8 T cells 408 and B cells had analogous nodes in the Bayesian networks 409 as assayed in the flow panel, while NK cells were mapped 410 to "active NK cells" in the Bayesian network. The relative 411 change in abundance was largely consistent among the four 412 systems, with the YUMM1.7 model being the most different. 413 NK cells were most reduced by CCN4, which was observed 414 in the B16F0 model and BRCA and SKCM datasets. A re-415 duction in CD8⁺ T cells by increased CCN4 expression was 416 consistent in both mouse models and both BRCA and SKCM 417 datasets. The CD4⁺ T cells seemed to vary where YUMM1.7 418 results seemed to be unaffected by CCN4 expression while 419 the BRCA and B16F0 results showed an increase and SKCM 420 showed a decrease. As stated previously, the BRCA and 421 SKCM predictions for CD4 T cells should be interpreted with 422 caution given the high frequency of zero values for the fea-423 tures. B cell response was mixed with both the BRCA and 424 SKCM results suggesting no change and an increase in the 425 B16F0 model and a decrease in the YUMM1.7 model, with 426 the low number of B cells infiltrating YUMM1.7 tumors ren-427 dered the results more variable. Given the small sample size 428 of the experimental mouse cohorts, only the extremes were 429

statistically significant, with NK cells significantly increased
 (p-value = 0.047) and B cells significantly decreased (p-value

⁴³² = 0.002) in B16F0 CCN4 KO tumors (Fig. 6D).

Concordance in CCN4-induced changes in the 433 myeloid compartment are less clear. In addition to 434 changes in T and NK cells within the live CD45⁺ compart-435 ment, we also assayed myeloid subsets in tumors generated 436 by wt and CCN4 KO variants of the B16F0 and YUMM1.7 437 cell lines. Using the gating strategy summarized in Figure 438 S10, we focused on CD11c⁺ and CD11c⁻ macrophages and 439 three different myeloid-derived suppressor cell (MDSC) sub-440 sets: granulocytic PMN-MDSC, monocytic Mo-MDSC, and 441 CD11c⁺ Mo-MDSC. In comparing tumors derived from wt 442 cell lines, CD11c⁺ macrophages were the most predomi-443 nant infiltrating myeloid cell subset and the CD11c⁺ sub-444 sets (macrophages and Mo-MDSC) were the most consis-445 tent (Fig. 7A). Upon CCN4 KO in the mouse models, the 446 macrophage subsets tended to increase while the MDSC sub-447 sets decreased (Fig. 7B-E) within the $CD45^+$ compartment. 448 The reduction in granulocytic PMN-MDSC in CCN4 KO 449 variants were most pronounced and statistically significant 450 (p=0.011 in B16F0 and p = 0.0011 in YUMM1.7). Con-451 versely, neutrophils were increased within the CD45⁺ com-452 partment in CCN4 KO tumors derived from YUMM1.7 cells 453 $(\log_{10} \text{ fraction in wt YUMM1.7: } -1.49\pm0.03 \text{ versus CCN4})$ 454 KO: -1.32 ± 0.09 , p = 0.041) but not statistically different in 455 the B16F0 model (p = 0.10). Other myeloid subsets trended 456 similarly but with differences that were not statistically sig-457 nificant, as expected given the small sample size. While 458 Ly6G and Ly6C staining may have been a better staining 459 strategy for distinguishing Mo-MDSC from PMN-MDSC, 460 Rose et al. reported that there are likely overlapping epi-461 topes between the Ly6G component of Gr1 and F4/80 (Rose 462 et al., 2012). When stained simultaneously (as done here), 463 the Gr1 antibody outcompetes the F4/80 mAb such that the 464 F4/80⁻ Gr1⁺ cells are likely Ly6G⁺ Ly6C⁻ (PMN-MDSC) 465 and the F4/80⁺ Gr1⁺ population is Ly6G⁻ Ly6C⁺ (Mo-466 MDSC) (see Fig. 7C and D). We observed a similar reduction 467 in PMN-MDSCs in YUMM1.7 tumors upon CCN4 KO using 468 Ly6G/Ly6C antibodies (Fernandez et al., 2020). 469

Comparing the trends in the myeloid compartment ob-470 served among the mouse models and the Bayesian network 471 predictions obtained from the BRCA and SKCM datasets is 472 less clear, given the uncertainty as to how the digital cytome-473 try features map onto the quantified myeloid subsets in these 474 mouse models. Key myeloid features in the Bayesian net-475 works were macrophages oriented towards a M1 phenotype. 476 Correspondingly, CD11c⁺ macrophages, a subset that has 477 been associated with pro-inflammatory M1 tumor-associated 478 macrophages (Jeong et al., 2019), were the most predominant 479 myeloid subset in wt B16F0 and YUMM1.7 tumors, which 480 didn't change upon CCN4 KO. In the BRCA dataset, the 481 prevalence of macrophages was influenced by CCN4 expres-482 sion; yet, the functional orientation away from the M2 and to-483 wards the M1 phenotype depended solely on oncogenic trans-484 formation. Similarly, the prevalence of macrophages was in-485 fluenced by both CCN4 expression and oncogenic transfor-486

mation in both melanoma datasets. In contrast to the BRCA 487 results, functional orientation of macrophages were indepen-488 dent of both oncogenic transformation and CCN4 expression. 489 Neutrophils were predicted to be independent of CCN4 in 490 the melanoma datasets, which is not surprising considering 491 that the majority of tumors had zero values for the Neu-492 trophil feature (see Figs. S1-S3). Similarly, neutrophils were 493 about 10 times less abundant than CD11c+ macrophages in 494 the mouse models. Given the significant changes observed 495 in MDSCs in the mouse models, challenging digital cytom-496 etry predictions in this way highlights features that can be 497 improved, such as discriminating among terminally differ-498 entiated and immature subsets, like Mo-MDSC and PMN-499 MDSC. 500

CCN4 has no direct effect on T cell proliferation but al-501 ters CD8⁺ T cell function. The local proliferation of CD8⁺ 502 T cells correlates with clinical response to immune check-503 point blockade (Huang et al., 2017; Twyman-Saint Victor 504 et al., 2015). In addition, the DAGs inferred from both the 505 breast cancer and melanoma datasets suggest that a decrease 506 in CD8⁺ T cells is driven indirectly through CCN4 via mod-507 ulating cancer-associated fibroblasts or the activity of NK 508 cells. While the structural learning algorithms rejected a di-509 rect edge between CCN4 and $CD8^+$ cells, we tested whether 510 CCN4 directly inhibits T cell proliferation (see Fig. 8A 511 and B) using a statistical analysis of Cell Trace distributions 512 in CD4⁺ and CD8⁺ T cells stimulated in vitro (see Table 513 S4). Specifically, splenocytes were stimulated in vitro with 514 α CD3/ α CD28-loaded beads in the presence of media condi-515 tioned by wt or CCN4 KO B16F0 cells or supplemented with 516 10 ng/ml recombinant mouse CCN4. In both the $CD4^+$ and 517 $CD8^+$ T cell populations, the presence of tumor-conditioned 518 media significantly inhibited the fraction of cells that divided 519 at least once (Dil - CD4 p-value = 0.022, CD8 p-value = 520 0.018) and the probability that a cell will divide at least once 521 (PF - CD4 p-value = 0.024, CD8 p-value = 0.013) while 522 CCN4 exposure was not a statistically significant factor. For 523 responding cells, the average number of divisions they un-524 dergo (PI) was not different among experimental conditions 525 for CD4⁺ T cells (p-value = 0.22) but reduced in CD8⁺ T 526 cells exposed to tumor-conditioned media (p-value = 0.0077). 527 Overall, the presence of tumor-conditioned media and not 528 CCN4 influenced T cell proliferation, which was consistent 529 with the DAGs. 530

Another characteristic of CD8⁺ T cells present within the 531 tumor microenvironment is that they are dysfunctional (Li 532 et al., 2019). As the digital cytometry approach used here 533 doesn't estimate the functional state of CD8⁺ T cells only 534 their prevalence within a tissue sample, we decided to test 535 whether CCN4 had a direct impact on CD8⁺ T cell func-536 tion, as quantified by target-specific ex vivo cytokine release 537 as measured by ELISpot. First we generated YUMM1.7-538 reactive CD8⁺ T cells by immunizing C57BL/6mice against 539 YUMM1.7 cells and isolated CD8a⁺ T cells from spleno-540 cytes three days after re-priming with live YUMM1.7 cells. 541 We also created a variant of CCN4 KO YUMM1.7 cells with 542 CCN4 expression induced by doxycycline and vector con-543

trols that were used as target cells (see Fig. S11). IFN γ 544 and TNF α ELISpots were used to quantify the CD8⁺ T cell 545 functional response to the different tumor targets in the pres-546 ence or absence of tumor-produced CCN4. As expected for 547 a re-call CD8a⁺ effector T cell response, the most prominent 548 IFN γ and lowest TNF α responses were against wt and CCN4 549 KO YUMM1.7 cells, with a slightly higher IFN γ response to 550 wt YUMM1.7 targets (see Fig. 8C, p-value < 0.05). Inter-551 estingly, re-expression of CCN4 by CCN4 KO YUMM1.7 552 cells following doxycycline induction significantly reduced 553 both IFN γ and TNF α production (p-value < 0.001), which 554 suggests that CCN4 plays a direct role in inhibiting CD8a⁺ 555 T cell function. Of note, CCN4 was predicted to directly in-556 hibit the activity of NK cells, which share cytokine release 557 and cytotoxicity mechanisms with CD8⁺ T cells. Overall, 558 the changes observed between wt and CCN4 KO variants 559 of the B16F0 and YUMM1.7 mouse models were consistent 560 with the causal networks inferred from the breast cancer and 561 melanoma datasets. 562

563 Discussion

Validating the role that a particular molecule plays in driving 564 the disease state using targeted experiments is central for im-565 proving understanding of biological mechanisms or selecting 566 among competing drug targets. Given the limited observabil-567 ity of the biological response in experimental models and pa-568 tients, mechanistic modeling and simulation is playing an in-569 creasing role in helping answer many central questions in dis-570 covering, developing, and receiving federal approval of phar-571 maceutical drugs and also basic biology (Moore and Allen, 572 2019). In immuno-oncology, there is increasing interest in 573 modeling the heterocellular network of relevance for a spe-574 cific immunotherapy. The first step in creating mathematical 575 models of cell-level networks is to create the topology of the 576 network, which is expressed in terms of which nodes to in-577 clude and how they influence each other. The structure of 578 these cell-level models is created using a fully supervised ap-579 proach, which means by hand using expert knowledge (Gad-580 kar et al., 2016). For instance, systems of ordinary differen-581 tial equations have been developed to capture multiple spa-582 tial compartments containing interacting malignant, antigen 583 presenting, and T cells and to predict a general immune re-584 sponse (Palsson et al., 2013), a response to immune check-585 point blockade using CTLA-4, PD-1, and PD-L1 antibodies 586 (Milberg et al., 2019) or adoptive cell transfer (Klinke and 587 Wang, 2016). 588

While leveraging the knowledge of experts is a great start-589 ing point, hand-curated models can also implicitly impose 590 bias on how data is interpreted. In the context of molecular-591 level networks, rules and algorithms have been developed 592 to elaborate causal networks based on a limited set of rules 593 (Chylek et al., 2014; Sekar and Faeder, 2012; Boutillier et al., 594 2018; Vernuccio and Broadbelt, 2019). The rules constrain 595 the types of interactions, or edges, that are realistic between 596 the nodes while the algorithms generate all possible edges 597 that are consistent with the rules and collection of nodes. The 598 resulting rule-based networks are then used to interpret data 599

by filter the edges for the most consistent and, in the process, 600 may reveal previously unappreciated pathways. For instance, 601 a rule-based model was used to interpret single-molecule de-602 tection of multisite phosphorylation on intact EGFR to re-603 veal new a role for the abundance of adaptor proteins to 604 redirect signaling (Salazar-Cavazos et al., 2020). Given the 605 challenges with representing the various activation states of 606 a 12-subunit Ca²⁺/calmodulin-dependent protein kinase II 607 (CaMKII) holoenzyme that is essential for memory function, 608 a rule-based model identified a molecular mechanism sta-609 bilizing protein activity that was obscured in prior reduced 610 models (Pharris et al., 2019). Inspired by engineering better 611 CAR T cells, Rohrs et al. developed a rule-based model to 612 interpret site-specific phosphorylation dynamics associated 613 with Chimeric Antigen Receptors (Rohrs et al., 2018). 614

To our knowledge, no equivalent approaches exist in the 615 context of modeling cell-level networks.¹ We posit that cou-616 pling digital cytometry with Bayesian network inference is 617 analogous to rule-based modeling in the context of modeling 618 cell-level networks. Here, the rules comprise a limited set of 619 constraints, or heuristics, related to the direction of informa-620 tion flow. Specifically, the rules limit how changes in gene 621 expression within the malignant cell introduced during onco-622 genesis propagate to stromal and immune cells present within 623 the tumor microenvironment and are implemented as a "black 624 list". The algorithms that underpin Bayesian network infer-625 ence search over all possible network topologies for edges 626 that are consistent with the data. The resulting networks can 627 be used in multiple ways. As an unsupervised approach, the 628 network topology could complement existing workflows for 629 creating mechanistic mathematical models fit for use in test-630 ing molecular targets (Gadkar et al., 2016; Ramanujan et al., 631 2019). In addition, DAGs represent explicit hypotheses gen-632 erated from pre-existing human data that motivate new exper-633 iments to validate the predictions, as illustrated by the B16F0 634 and YUMM1.7 results. 635

While the focus here is in the context of breast cancer 636 and melanoma due the pre-existing breadth of data, the ap-637 proach could be generally applied to other biological con-638 texts and motivate new experimental studies. For instance, 639 one of the limitations of inferring the network topology in 640 the form of directed acyclic graphs is that some direct and in-641 direct causal relationships can be confounded, such as recip-642 rocal feedback modes of communication between cells (Zhou 643 et al., 2018). Discerning the difference between a direct and 644 indirect causal relationship has practical importance, such as 645 for selecting therapeutic targets (Pearl, 2005). Methods, like 646

¹One might consider agent-based or cellular automata models to apply as the cellular interactions are specified by rules. In rule-based modeling of molecular networks, the rules and algorithms elaborate a network space that encompasses all possible topologies of the network and data is used to prune the network to the most relevant. Similarly, the edges included in the "blacklist" and "whitelists" can be considered as a Bayesian prior, where the strength of inclusion in the final DAG and the coefficient associated with a particular edge in the conditional probability function depend on the data. In contrast, agent-based or cellular automata models require specifying all interactions between cells as rules a priori and are validated qualitatively by comparing emergent behavior against experimental observations (Hwang et al., 2009; López et al., 2017; Mallet and De Pillis, 2006).

Granger causality and dynamic Bayesian networks (Finkle 647 et al., 2018; Li et al., 2014; Zou and Conzen, 2005), do ex-648 ist that could reveal direct and indirect causal relationships, 649 but time-series data is required. Unfortunately, human tis-650 sue samples, like those in the TGCA, are very rarely sampled 651 with time. Analysis of pre-existing human datasets can be 652 complemented by a more focused experimental study of a 653 pre-clinical model. Specifically, single-cell RNAseq to iden-654 tify the cell types present and their associated gene signatures 655 can be combined with bulk transcriptomic sequencing to cap-656 ture the prevalence of all of the cell types within the tissue 657 sample and provide a large number of biological replicates 658 spanning the disease space - normal homeostasis; initiation; 659 early, middle and late progression; and productive resolution 660 or adverse outcomes. Similar network topologies would sug-661 gest similar biological mechanisms and help select relevant 662 pre-clinical models for drug development. In short, we feel 663 that combining digital cytometry with Bayesian network in-664 ference has the potential to become an indispensable unsu-665 pervised approach for discovering relevant heterocellular net-666 works associated with disease. 667

668 Methods

Digital Cytometry. Transcriptomics profiling of bulk tissue 669 samples using Illumina RNA sequencing for the breast can-670 cer (BRCA) and cutaneous melanoma (SKCM) arms of the 671 Cancer Genome Atlas was downloaded from TCGA data 672 commons, where values for gene expression were expressed 673 in counts using the "TCGAbiolinks" (V2.8.2) package in R 674 (V3.6.1) and converted to TPM. RNA-seq data expressed in 675 counts assayed in samples acquired from benign melanocytic 676 nevi and untreated primary melanoma tissue and associ-677 ated sample annotation were downloaded from GEO entry 678 GSE98394 and converted to TPM. TCGA data and the be-679 nign nevi and melanoma data were filtered to remove sam-680 ple outliers and normalized based on housekeeping gene ex-681 pression (Eisenberg and Levanon, 2013). Digital cytometry 682 features associated with the functional plasticity of tumor 683 cells within an epithelial to mesenchymal-like state space 684 were calculated based on state metrics developed separately 685 for bulk breast cancer and melanoma tissue samples (Klinke 686 and Torang, 2020). Cell proliferation features were calcu-687 lated based on the median expression of genes associated 688 with cell proliferation identified previously using human cell 689 line data (Deng et al., 2020). Features corresponding to 690 the prevalence of endothelial cells, cancer-associated fibrob-691 lasts, macrophages, and CD4+ T cells were calculated us-692 ing CIBERSORTx (https://cibersortx.stanford.edu) using the 693 gene signatures derived from single cell RNAseq data (Tirosh 694 et al., 2016) while the prevalence of B cells naïve, CD8⁺ 695 T cells, Macrophage M0 ($M\Phi 0$), Macrophage M1 ($M\Phi 1$), 696 Macrophage M2 ($M\Phi2$), activated NK cells, resting NK 697 cells, and neutrophils were calculated using the LM22 im-698 mune cell gene signatures in CIBERSORTx run in absolute 699 mode. 700

⁷⁰¹ Given the potential lack of independence among the ⁷⁰² macrophage features, the LM22 macrophage features were combined to estimate the probability of the average functional orientation using the formula described previously(Kaiser et al., 2016): 703

$$p(M\Phi i) = \frac{M\Phi i}{M\Phi 0 + M\Phi 1 + M\Phi 2},$$
 (1) 706

where $i = \{0, 1, 2\}$ and denotes the specific macrophage sub-707 type. Additional cellular features were excluded from the 708 analysis as they tended to have a large number of zero val-709 ues across the datasets or were disconnected from the rest of 710 the network in preliminary network inference studies. Sam-711 ple attributes were transformed to numerical values, which 712 were assumed to be extremes of a continuous variable (e.g., 713 Normal = 0, Cancer = 1). The sample attributes, CCN4 gene 714 expression, and estimated cellular features extracted from the 715 bulk RNAseq data calculated for each sample are included in 716 the GitHub repository. 717

Bayesian Network Inference. Prior to network inference, 718 feature values were log transformed, normalized to values 719 between 0 and 1, and discretized (BRCA: 15 intervals; GEO 720 and SKCM: 6 intervals), as summarized in supplemental Fig-721 ures S1-S3. The features were then assigned to nodes. The 722 relationships among the nodes, or edges, were represented 723 by directed acyclic graphs inferred from the datasets using a 724 two-stage process, as detailed in the results section. Given 725 the inferred structure, a Bayesian network in the form of a 726 linear Gaussian model was fit to the datasets using maximum 727 likelihood estimation of the model parameters. Conditional 728 probability queries of the Bayesian networks were performed 729 by logic sampling with 10^5 samples. Bayesian network infer-730 ence was performed using the 'bnlearn' package (V4.5) in R 731 (V3.6.1). 732

Reagents and Cell Culture. Cytokines and antibodies 733 were obtained from commercial sources and used accord-734 ing to the suppliers' recommendations unless otherwise in-735 dicated. The mouse melanoma line B16F0 (purchased 736 in 2008, RRID: CVCL 0604) was obtained from Ameri-737 can Tissue Culture Collection (ATCC, Manassas, VA). The 738 mouse melanoma line YUMM1.7 (received in September 739 2017, RRID: CVCL_JK16) was a gift from Drs. William 740 E. Damsky and Marcus W. Bosenberg (Yale University) 741 (Meeth et al., 2016). B16F0 and YUMM1.7 cells were 742 cultured at 37°C in 5% CO2 in high-glucose DMEM 743 (Cellgro/Corning) supplemented with L-glutamine (Lonza), 744 penicillin-streptomycin (Gibco), and 10% heat-inactivated 745 fetal bovine serum (Hyclone). All cell lines were revived 746 from frozen stock, used within 10-15 passages that did not 747 exceed a period of 6 months, and routinely tested for my-748 coplasma contamination by PCR. CCN4 knock-out vari-749 ants of B16F0 and YUMM1.7 cells were generated using a 750 double-nickase CRISPR/Cas9 editing strategy described pre-751 viously (Deng et al., 2019). Briefly, two pairs of mouse 752 CCN4 double nickase plasmids that target the mouse CCN4 753 gene at different locations were purchased from Santa Cruz 754 Biotechnology, Inc. (Dallas, TX) and transfected into B16F0 755

and YUMM1.7 cells following the manufacturer's instructions. Following antibiotic selection, surviving single clones
were isolated and expanded on 6-well plates. The concentration of CCN4 in the cell culture media from those wells
was assayed using the Human WISP-1/CCN4 DuoSet ELISA
Kit (R&D Systems, Minneapolis, MN) to confirm CCN4

⁷⁶² knockout. CCN4-knockout cells were further expanded and

⁷⁶³ aliquoted to create a low passage frozen stock.

In vivo Tumor Assays and in vitro T cell proliferation 764 assays. All animal experiments were approved by West Vir-765 ginia University (WVU) Institutional Animal Care and Use 766 Committee and performed on-site. C57BL/6Ncrl mice (6-767 8 week-old female) were from Charles River Laboratories. 768 Mice were randomly assigned to treatment groups and co-769 housed following tumor initiation. Subcutaneous tumors 770 were initiated by injecting mice subcutaneously with 3×10^5 771 of the indicated YUMM1.7 cells and 2.2×10^5 of the in-772 dicated B16F0 cells in 100 μ L and, once palpable, tumor 773 sizes were recorded every other day via caliper. Tumor vol-774 ume was calculated using the formula: $0.5236 \text{ x width}^2 \text{ x}$ 775 length, where the width is the smaller dimension of the tu-776 mor. Once WT tumors reached between 1000 and 1500 mm³ 777 in size, the tumors were surgically removed from mice in 778 both arms of the study (WT and CCN4 KO) after euthana-779 sia and processed into single cell suspensions. This normally 780 occurred at Day 14 with the B16F0 model and at Day 27 781 with the YUMM1.7 model. Three tumors were processed 782 separately for each YUMM1.7 variant while four tumors 783 were processed for each B16F0 variant. Single-cell suspen-784 sions were obtained by enzymatically digesting the excised 785 tumors using the Tumor Dissociation Kit and gentleMACS 786 C system (Miltenyi Biotec, Auburn, CA). In addition to 787 following the manufacturer's instructions, the gentleMACS 788 program 37C m TDK 1 was used for B16F0 tumors and 789 37C_m_TDK_2 was used for YUMM1.7 tumors. Following 790 lysing of the red blood cells, the remaining single-cell sus-791 pensions were washed and stained with Live/Dead Fixable 792 Pacific Blue Dead Cell Stain Kit (ThermoFisher). Following 793 blocking with Mouse BD Fc Block (BD Biosciences), the 794 surface of the cells were stained with one of three different 795 antibody mixes that focused on T cells (CD45, CD3, CD4, 796 CD8, and PD1), NK and B cells (CD45, B220, NK11, DX5, 797 and PD1), and myeloid cells (CD45, CD11b, CD11c, Gr-1, 798 F4/80, and MHCII) and quantified by flow cytometry. The 799 specific antibodies used are listed in Supplemental Table S1. 800

To assess the impact of CCN4 on T cell proliferation 801 in vitro, splenocytes were obtained from naïve C57BL/6 802 mice and stained with CellTrace Pacific Blue Cell Prolifer-803 ation Kit (ThermoFisher). Stained splenocytes (2.5×10^5) 804 were stimulated for 3 days in 96 well plate with MACSi-805 Beads loaded with anti-mouse CD3 and anti-mouse CD28 806 antibodies (AP beads, Miltenyi Biotec), at a 1:1 propor-807 tion. Fresh serum-free DMEM media conditioned for 24 808 hours by either confluent wild-type (WT TCM) or conflu-809 ent CCN4 KO (CCN4 KO TCM) melanoma B16F0 cells 810 were collected, centrifuged to remove cells and cell debris, 811 and added at 50% final volume during T cell stimulation 812

with AP beads. In addition, splenocytes were either left 813 unstimulated or stimulated with AP beads alone, or stimu-814 lated in the presence of recombinant mouse CCN4 (rCCN4, 815 R&D) at a final concentration of 10 ng/mL. After 72h, cells 816 were washed and stained with Live/Dead Fixable Green Dead 817 Cell Stain Kit (ThermoFisher). Surface staining with anti-818 mouse CD8/APC (Miltenyi Biotec), anti-mouse CD4/APC-819 Cy7 (BD Biosciences), anti-mouse CD62L/PE (eBioscience, 820 ThermoFisher) and anti-mouse CD44/PerCPCy5.5 (eBio-821 science, ThermoFisher) was performed after incubating the 822 cells with Mouse BD Fc Block (BD Biosciences). The pro-823 liferation of both CD4 and CD8 T cells were quantified by 824 flow cytometry. 825

In vitro suppression of CD8⁺ T cell function. Inducible 826 mouse CCN4 expression lentiviral vector (IDmCCN4) was 827 constructed with Gateway cloning using Tet-on destination 828 lentiviral vector pCW57.1 (Addgene Plasmid #41393, a 829 gift from David Root) and pShuttle Gateway PLUS ORF 830 Clone for mouse CCN4 (GC-Mm21303, GeneCopoeia). 831 Lentiviruses were packaged as described (Deng et al., 2019) 832 to transduce YUMM1.7 cell with Ccn4 CRISPR knockout 833 (Ym1.7-KO1) (Deng et al., 2019). After puromycin selec-834 tion, two pools of cells with inducible mCCN4 (Ym1.7-835 KO1-IDmCCN4) or vector control (Ym1.7-KO1-IDvector) 836 were obtained. ELISA tests with doxycycline (Dox, final 837 0.5µg/ml) induction revealed the mCCN4 expression was un-838 der stringent control and the secreted protein was in the sim-839 ilar level as compared with wild-type YUMM1.7 cells (data 840 not shown). 841

To generate YUMM1.7-reactive CD8+ T cells, healthy 842 C57BL/6Ncrl mice were inoculated subcutaneously with 843 irradiated YUMM1.7 cells (10⁵/mouse), followed by live 844 YUMM1.7 cells (3×10^5 /mouse) 3 weeks later. The mice 845 without tumor growth in the next five weeks were main-846 tained. Three days before the assay, the mice were injected 847 again with live YUMM1.7 cells (10^{5} /mouse). On the day 848 of assay, these mice were euthanized and the YUMM1.7-849 reactive cells were isolated from mouse splenocytes using 850 mouse CD8a+ T Cell Isolation Kit (130-104-075, Miltenyi 851 Biotec), resuspended in a concentration of 10^6 /ml. 50μ l 852 (5×10^4) of the YUMM1.7-reactive CD8+ T cells were 853 aliquoted into each well on a 96-well plate for ELISpot assay 854 using Mouse IFN γ /TNF α Double-Color ELISpot kit (Cellu-855 lar Technology Limited, CTL) following manufacturer's in-856 structions. Briefly, target tumor cells were stimulated with 857 IFN γ (200U/ml, or, 20ng/ml) for 24 hours, harvested and 858 resuspended in a concentration of 2×10^6 /ml. $50 \mu l$ (10⁵) 859 of indicated tumor cells in triplicates were aliquoted into 860 each well, with or without doxycycline (Dox, final 0.5μ g/ml). 861 The reactions were incubated at 37°C for 24 hours and 862 colored spots were developed (Red for IFN γ and blue for 863 TNF α). The spots were counted and imaged using an Olym-864 pus MVX10 Microscope and the result was plotted and ana-865 lyzed by GraphPad Prism (version 5). 866

Flow Cytometry. Single cell suspensions described above were stained with specific antibodies or isotype controls 868

using conventional protocols. Fluorescence-activated cell 869 counting was performed using a BD LSRFortessa and FACS-870 Diva software (BD Biosciences) as where the fluorescence 871 intensity for each parameter was reported as a pulse area 872 with 18-bit resolution. Unstained samples were used as nega-873 tive flow cytometry controls. Single-stain controls were used 874 to establish fluorescence compensation parameters. For TIL 875 analysis, greater than 5×10^5 events were acquired in each 876 antibody panel in each biological replicate. In analyzing en-877 riched cell populations, 2×10^4 events were acquired in each 878 biological replicate. Flow cytometric data were exported 879 as FCS3.0 files and analyzed with using R/Bioconductor 880 (V3.5.1), as described previously (Klinke and Brundage, 881 2009). The typical gating strategies for T cells, NK and B 882 cells, and myeloid cells are shown in supplementary Figures 883 S4-S6, respectively. The statistical difference in tumor infil-884 trating lymphocytes between wt and CCN4 KO variants was 885 assessed using log-transformed values and a two-tailed ho-886 moscedastic Student's t test. Cell proliferation was quantified 887 using metrics: fraction diluted (Dil), Precursor frequency, 888 % dividing cells (PF), Proliferation index (PI), and prolifer-889 ation variance (SD^D) (Roederer, 2011). Statistical differ-890 ences among these proliferation parameters were assessed us-891 ing type III repeated measures ANOVA in the "car" (V3.0-7) 892 package in R. A p-value < 0.05 was considered statistically 893 significant. 894

Data and Code Availability. The code used in the analysis can be obtained from the following GitHub repository:

• https://github.com/KlinkeLab/CellNetwork_2020

898 ACKNOWLEDGEMENTS

This work was supported by National Science Foundation (NSF CBET-1644932
 to DJK) and National Cancer Institute (NCI 1R01CA193473 to DJK). The content is
 solely the responsibility of the authors and does not necessarily represent the official
 views of the NSF or NCI. We also used equipment from the WVU Flow Cytometry
 & Single Cell core, which was supported by the National Institutes of Health Grants
 GM103488/RR032138, GM104942, GM103434, and OD016165.

AUTHOR CONTRIBUTIONS

These contributions follow the International Committee of Medical Journal Editors guidelines: http://www.icmje.org/recommendations/. Conceptualization: DJK;
 Study Design: DJK; Data Acquisition: DJK, AF, and WD; Data Analysis: DJK
 and WD; Data Interpretation: DJK; Funding acquisition: DJK; Methodology: DJK;
 Project administration: DJK; Software: DJK and ACP; Supervision: DJK; Writing original draft: DJK; Writing - review & editing: all authors.

912 COMPETING FINANCIAL INTERESTS

913 The authors declare no competing financial interests.

914 Bibliography

905

- Becht, E., Giraldo, N.A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent Puig, P., Sautes-Fridman, C., Fridman, W.H., de Reynies, A., 2016. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression.
 Genome Biol. 17, 218.
- Boutillier, P., Maasha, M., Li, X., Medina-Abarca, H.F., Krivine, J., Feret, J., Cristescu, I., Forbes,
 A.G., Fontana, W., 2018. The Kappa platform for rule-based modeling. Bioinformatics 34,
 i583–i592.
- Chylek, L.A., Harris, L.A., Tung, C.S., Faeder, J.R., Lopez, C.F., Hlavacek, W.S., 2014. Rulebased modeling: a computational approach for studying biomolecular site dynamics in cell signaling systems. Wiley Interdiscip Rev Syst Biol Med 6, 13–36.
- Deng, W., Fernandez, A., McLaughlin, S.L., Klinke, D.J., 2019. WNT1-inducible signaling pathway
 protein 1 (WISP1/CCN4) stimulates melanoma invasion and metastasis by promoting the
 epithelial-mesenchymal transition. J. Biol. Chem. 294, 5261–5280.
- Deng, W., Fernandez, A., McLaughlin, S.L., Klinke, D.J., 2020. Cell Communication Network
 Factor 4 (CCN4/WISP1) Shifts Melanoma Cells from a Fragile Proliferative State to a Resilient
 Metastatic State. Cell Mol Bioeng 13, 45–60.
- Eisenberg, E., Levanon, E.Y., 2013. Human housekeeping genes, revisited. Trends Genet. 29, 569–574.

Fernandez, A., Deng, W., McLaughlin, S., Pirkey, A., Rellick, S., Klinke, D.J., 2020. Cell communication network factor 4 (ccn4/wisp1) promotes tumor-induced immunosuppression in melanoma. bioRxiv (submitted).

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

Finkle, J.D., Wu, J.J., Bagheri, N., 2018. Windowed Granger causal inference strategy improves discovery of gene regulatory networks. Proc. Natl. Acad. Sci. U.S.A. 115, 2252–2257.

Friedman, N., 2004. Inferring cellular networks using probabilistic graphical models. Science 303, 799–805.

- Gadkar, K., Kirouac, D.C., Mager, D.E., van der Graaf, P.H., Ramanujan, S., 2016. A Six-Stage Workflow for Robust Application of Systems Pharmacology. CPT Pharmacometrics Syst Pharmacol 5, 235–249.
- George, J.T., Jolly, M.K., Xu, S., Somarelli, J.A., Levine, H., 2017. Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. Cancer Res. 77, 6415– 6428.
- Grun, D., Kester, L., van Oudenaarden, A., 2014. Validation of noise models for single-cell transcriptomics. Nat. Methods 11, 637–640.
- Hill, S.M., Heiser, L.M., Cokelaer, T., Unger, M., Nesser, N.K., Carlin, D.E., Zhang, Y., Sokolov, 948 A., Paull, E.O., Wong, C.K., Graim, K., Bivol, A., Wang, H., Zhu, F., Afsari, B., Danilova, L.V., 949 Favorov, A.V., Lee, W.S., Taylor, D., Hu, C.W., Long, B.L., Noren, D.P., Bisberg, A.J., Mills, 950 G.B., Gray, J.W., Kellen, M., Norman, T., Friend, S., Qutub, A.A., Fertig, E.J., Guan, Y., Song, 951 M., Stuart, J.M., Spellman, P.T., Koeppl, H., Stolovitzky, G., Saez-Rodriguez, J., Mukherjee, 952 S., Afsari, B., Al-Ouran, R., Anton, B., Arodz, T., Sichani, O.A., Bagheri, N., Berlow, N., 953 Bisberg, A.J., Bivol, A., Bohler, A., Bonet, J., Bonneau, R., Budak, G., Bunescu, R., Caglar, 954 M., Cai, B., Cai, C., Carlin, D.E., Carlon, A., Chen, L., Ciaccio, M.F., Cokelaer, T., Cooper, G., 955 Coort, S., Creighton, C.J., Daneshmand, S.M., de la Fuente, A., Di Camillo, B., Danilova, L.V., 956 Dutta-Moscato, J., Emmett, K., Evelo, C., Fassia, M.K., Favorov, A.V., Fertig, E.J., Finkle, J.D., 957 Finotello, F., Friend, S., Gao, X., Gao, J., Garcia-Garcia, J., Ghosh, S., Giaretta, A., Graim, 958 K., Gray, J.W., Grosseholz, R., Guan, Y., Guinney, J., Hafemeister, C., Hahn, O., Haider, S., 959 Hase, T., Heiser, L.M., Hill, S.M., Hodgson, J., Hoff, B., Hsu, C.H., Hu, C.W., Hu, Y., Huang, 960 X., Jalili, M., Jiang, X., Kacprowski, T., Kaderali, L., Kang, M., Kannan, V., Kellen, M., Kikuchi, 961 K., Kim, D.C., Kitano, H., Knapp, B., Komatsoulis, G., Koeppl, H., Kramer, A., Kursa, M.B., 962 Kutmon, M., Lee, W.S., Li, Y., Liang, X., Liu, Z., Liu, Y., Long, B.L., Lu, S., Lu, X., Manfrini, 963 M., Matos, M.R., Meerzaman, D., Mills, G.B., Min, W., Mukherjee, S., Muller, C.L., Neapolitan, 964 R.E., Nesser, N.K., Noren, D.P., Norman, T., Oliva, B., Opiyo, S.O., Pal, R., Palinkas, A., Paull, 965 E.O., Planas-Iglesias, J., Poglayen, D., Qutub, A.A., Saez-Rodriguez, J., Sambo, F., Sanavia, 966 T., Sharifi-Zarchi, A., Slawek, J., Sokolov, A., Song, M., Spellman, P.T., Streck, A., Stolovitzky, 967 G., Strunz, S., Stuart, J.M., Taylor, D., Tegner, J., Thobe, K., Toffolo, G.M., Trifoglio, E., Unger, 968 M., Wan, Q., Wang, H., Welch, L., Wong, C.K., Wu, J.J., Xue, A.Y., Yamanaka, R., Yan, C., 969 Zairis, S., Zengerling, M., Zenil, H., Zhang, S., Zhang, Y., Zhu, F., Zi, Z., 2016. Inferring causal 970 molecular networks: empirical assessment through a community-based effort. Nat. Methods 971 13.310-318. 972
- Hoadley, K.A., Yau, C., Hinoue, T., Wolf, D.M., Lazar, A.J., Drill, E., Shen, R., Taylor, A.M., Cherniack, A.D., Thorsson, V., Akbani, R., Bowlby, R., Wong, C.K., Wiznerowicz, M., Sanchez-Vega, F., Robertson, A.G., Schneider, B.G., Lawrence, M.S., Noushmehr, H., Malta, T.M., Cancer Genome Atlas Network, Stuart, J.M., Benz, C.C., Laird, P.W., 2018. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173, 291–304.
- Huang, A.C., Postow, M.A., Orlowski, R.J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J.R., Wenz, B., Adamow, M., Kuk, D., Panageas, K.S., Carrera, C., Wong, P., Quagliarello, F., Wubbenhorst, B., D'Andrea, K., Pauken, K.E., Herati, R.S., Staupe, R.P., Schenkel, J.M., McGettigan, S., Kothari, S., George, S.M., Vonderheide, R.H., Amaravadi, R.K., Karakousis, G.C., Schuchter, L.M., Xu, X., Nathanson, K.L., Wolchok, J.D., Gangadhar, T.C., Wherry, E.J., 2017. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60–65.
- Hwang, M., Garbey, M., Berceli, S.A., Tran-Son-Tay, R., 2009. Rule-Based Simulation of Multi-Cellular Biological Systems-A Review of Modeling Techniques. Cell Mol Bioeng 2, 285–294.
- Jeong, H., Hwang, I., Kang, S.H., Shin, H.C., Kwon, S.Y., 2019. Tumor-Associated Macrophages as Potential Prognostic Biomarkers of Invasive Breast Cancer. J Breast Cancer 22, 38–51.
- Kaiser, J.L., Bland, C.L., Klinke, D.J., 2016. Identifying causal networks linking cancer processes and anti-tumor immunity using Bayesian network inference and metagene constructs. Biotechnol. Prog. 32, 470–479.
- Klinke, D.J., 2014. Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study. PLoS Comput. Biol. 10, e1003409.
- Klinke, D.J., 2016. Eavesdropping on altered cell-to-cell signaling in cancer by secretome profiling. Mol Cell Oncol 3, e1029061.
- Klinke, D.J., Brundage, K.M., 2009. Scalable analysis of flow cytometry data using R/Bioconductor. Cytometry A 75, 699–706.
- Klinke, D.J., Torang, A., 2020. An unsupervised feature extraction and selection strategy for identifying epithelial-mesenchymal transition state metrics in breast cancer and melanoma. iScience, (in press).
- Klinke, D.J., Wang, Q., 2016. Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation. Front Pharmacol 7, 515.
- Koplev, S., Lin, K., Dohlman, A.B., Ma'ayan, A., 2018. Integration of pan-cancer transcriptomics with RPPA proteomics reveals mechanisms of epithelial-mesenchymal transition. PLoS Comput. Biol. 14, e1005911.
- Li, H., van der Leun, A.M., Yofe, I., Lubling, Y., Gelbard-Solodkin, D., van Akkooi, A.C.J., van den Braber, M., Rozeman, E.A., Haanen, J.B.A.G., Blank, C.U., Horlings, H.M., David, E., Baran, Y., Bercovich, A., Lifshitz, A., Schumacher, T.N., Tanay, A., Amit, I., 2019. Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. Cell 176, 775–789.
- Li, P., Gong, P., Li, H., Perkins, E.J., Wang, N., Zhang, C., 2014. Gene regulatory network inference and validation using relative change ratio analysis and time-delayed dynamic Bayesian network. EURASIP J Bioinform Syst Biol 2014, 12.
- López, A.G., Seoane, J.M., Sanjuán, M.A.F., 2017. Dynamics of the cell-mediated immune response to tumour growth. Philos Trans A Math Phys Eng Sci 375.

- Mallet, D.G., De Pillis, L.G., 2006. A cellular automata model of tumor-immune system interactions. J. Theor. Biol. 239, 334–350.
- Malta, T.M., Sokolov, A., Gentles, A.J., Burzykowski, T., Poisson, L., Weinstein, J.N., Kami/nska,
 B., Huelsken, J., Omberg, L., Gevaert, O., Colaprico, A., Czerwi/nska, P., Mazurek, S.,
 Mishra, L., Heyn, H., Krasnitz, A., Godwin, A.K., Lazar, A.J., Cancer Genome Atlas Research Network, Stuart, J. M. Hoadley, K.A., Laird, P.W., Noushmehr, H., Wiznerowicz, M.,
 2018. Machine Learning Identifies Stemness Features Associated with Oncogenic Dediffer-
- dettaining Learning addition of the second states of the se
- Medan, Ha, Hang, Osh, Michel, G., Ballisty, H., Estenberg, M.T., Ester The Formit most a series of congenic mouse melanoma cell lines with defined genetic alterations. Pigment Cell Melanoma Res 29, 590–597.
- Milberg, O., Gong, C., Jafarnejad, M., Bartelink, I.H., Wang, B., Vicini, P., Narwal, R., Roskos,
 L., Popel, A.S., 2019. A QSP Model for Predicting Clinical Responses to Monotherapy, Com bination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade.
 Sci Rep 9, 11286.
- Moore, H., Allen, R., 2019. What Can Mathematics Do for Drug Development? Bull. Math. Biol.
 81, 3421–3424.
- Newman, A.M., Steen, C.B., Liu, C.L., Gentles, A.J., Chaudhuri, A.A., Scherer, F., Khodadoust,
 M.S., Esfahani, M.S., Luca, B.A., Steiner, D., Diehn, M., Alizadeh, A.A., 2019. Determining
 cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol.
 37, 773–782.
- Palsson, S., Hickling, T.P., Bradshaw-Pierce, E.L., Zager, M., Jooss, K., O'Brien, P.J., Spilker,
 M.E., Palsson, B.O., Vicini, P., 2013. The development of a fully-integrated immune response
 model (FIRM) simulator of the immune response through integration of multiple subset mod els. BMC Syst Biol 7, 95.
- Papalexi, E., Satija, R., 2018. Single-cell RNA sequencing to explore immune cell heterogeneity.
 Nat. Rev. Immunol. 18, 35–45.
- Pearl, J., 2005. Direct and indirect effects, in: Proc Am Stat Assoc Joint Stat Meetings (Minneapolis, MN), MIRA Digital Publishing. pp. 1572–1581.
- Perrin, B.E., Ralaivola, L., Mazurie, A., Bottani, S., Mallet, J., dlchBuc, F., 2003. Gene networks
 inference using dynamic bayesian networks. Bioinformatics 19, ii138–ii148.
- Pharris, M.C., Patel, N.M., VanDyk, T.G., Bartol, T.M., Sejnowski, T.J., Kennedy, M.B., Stefan,
 M.I., Kinzer-Ursem, T.L., 2019. A multi-state model of the CaMKII dodecamer suggests a role
 for calmodulin in maintenance of autophosphorylation. PLoS Comput. Biol. 15, e1006941.
- Ramanujan, S., Chan, J.R., Friedrich, C.M., Thalhauser, C.J., 2019. A Flexible Approach for Context-Dependent Assessment of Quantitative Systems Pharmacology Models. CPT Pharmacometrics Syst Pharmacol 8, 340–343.
- Roederer, M., 2011. Interpretation of cellular proliferation data: avoid the panglossian. Cytometry
 A 79, 95–101.
- Rohrs, J.A., Zheng, D., Graham, N.A., Wang, P., Finley, S.D., 2018. Computational Model of Chimeric Antigen Receptors Explains Site-Specific Phosphorylation Kinetics. Biophys. J. 115, 1116–1129.
- 1061 Rose, S., Misharin, A., Perlman, H., 2012. A novel Ly6C/Ly6G-based strategy to analyze the 1062 mouse splenic myeloid compartment. Cytometry A 81, 343–350.
- 1063 Sachs, K., Gifford, D., Jaakkola, T., Sorger, P., Lauffenburger, D.A., 2002. Bayesian network approach to cell signaling pathway modeling. Science Signaling 2002, pe38.
- 1065 Sachs, K., Itani, S., Carlisle, J., Nolan, G.P., Pe'er, D., Lauffenburger, D.A., 2009. Learning 1066 signaling network structures with sparsely distributed data. J Comp Biol 16, 201–212.
- 1067 Sachs, K., Perez, O., Pe'er, D., Lauffenburger, D.A., Nolan, G.P., 2005. Causal protein-signaling networks derived from multiparameter single-cell data. Science 308, 523–529.
- Salazar-Cavazos, E., Nitta, C.F., Mitra, E.D., Wilson, B.S., Lidke, K.A., Hlavacek, W.S., Lidke,
 D.S., 2020. Multisite EGFR phosphorylation is regulated by adaptor protein abundances and
 dimer lifetimes. Mol. Biol. Cell 31. 695–708.
- Schelker, M., Feau, S., Du, J., Ranu, N., Klipp, E., MacBeath, G., Schoeberl, B., Raue, A.,
 2017. Estimation of immune cell content in tumour tissue using single-cell RNA-seq data. Nat
 Commun 8, 2032.
- 1075 Scutari, M., 2010. Learning Bayesian Networks with the bnlearn R Package. J Stat Software 35, 1076 1–22.
- Sekar, J.A., Faeder, J.R., 2012. Rule-based modeling of signal transduction: a primer. Methods Mol. Biol. 880, 139–218.
- Shen-Orr, S., Tibshirani, R., Butte, A., 2012. Gene expression deconvolution in linear space.
 Nature Methods 9, 9.
- Shen-Orr, S.S., Tibshirani, R., Khatri, P., Bodian, D.L., Staedtler, F., Perry, N.M., Hastie, T., Sarwal, M.M., Davis, M.M., Butte, A.J., 2010. Cell type-specific gene expression differences in complex tissues. Nat. Methods 7, 287–289.
- Singer, M., Anderson, A.C., 2019. Revolutionizing Cancer Immunology: The Power of Next-Generation Sequencing Technologies. Cancer Immunol Res 7, 168–173.
- 1086 Stuart, T., Satija, R., 2019. Integrative single-cell analysis. Nat. Rev. Genet. 20, 257-272.
- Tan, T.Z., Miow, Q.H., Miki, Y., Noda, T., Mori, S., Huang, R.Y., Thiery, J.P., 2014. Epithelial mesenchymal transition spectrum quantification and its efficacy in deciphering survival and
 drug responses of cancer patients. EMBO Mol Med 6, 1279–1293.
- Thorsson, V., Gibbs, D.L., Brown, S.D., Wolf, D., Bortone, D.S., Ou Yang, T.H., Porta-Pardo, E.,
 Gao, G.F., Plaisier, C.L., Eddy, J.A., Ziv, E., Culhane, A.C., Paull, E.O., Sivakumar, I.K.A.,
 Gentles, A.J., Malhotra, R., Farshidfar, F., Colaprico, A., Parker, J.S., Mose, L.E., Vo, N.S.,
 Liu, J., Liu, Y., Rader, J., Dhankani, V., Reynolds, S.M., Bowlby, R., Califano, A., Cherniack,
 A.D., Anastassiou, D., Bedognetti, D., Rao, A., Chen, K., Krasnitz, A., Hu, H., Malta, T.M.,
- Noushmehr, H., Pedamallu, C.S., Bullman, S., Ojesina, A.I., Lamb, A., Zhou, W., Shen, H.,
 Choueiri, T.K., Weinstein, J.N., Guinney, J., Saltz, J., et al., 2018. The Immune Landscape of
 Cancer. Immunity 48, 812–830.
- Tirosh, I., Izar, B., Prakadan, S.M., Wadsworth, M.H., Treacy, D., Trombetta, J.J., Rotem, A.,
 Rodman, C., Lian, C., Murphy, G., Fallahi-Sichani, M., Dutton-Regester, K., Lin, J.R., Co hen, O., Shah, P., Lu, D., Genshaft, A.S., Hughes, T.K., Ziegler, C.G., Kazer, S.W., Gaillard,
- A., Kolb, K.E., Villani, A.C., Johannessen, C.M., Andreev, A.Y., Van Allen, E.M., Bertagnolli,
 M., Sorger, P.K., Sullivan, R.J., Flaherty, K.T., Frederick, D.T., Jane-Valbuena, J., Yoon, C.H.,
- Rozenblatt-Rosen, O., Shalek, A.K., Regev, A., Garraway, L.A., 2016. Dissecting the multi-
- cellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196.

- Torang, A., Gupta, P., Klinke, D.J., 2019. An elastic-net logistic regression approach to generate classifiers and gene signatures for types of immune cells and T helper cell subsets. BMC Bioinformatics 20, 433. 1107
- Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W., Pagos, F., Galon, J., 2011. Clinical impact of different classes of infiltrating t cytotoxic and helper cells (th1, th2, treg, th17) in patients with colorectal cancer. Cancer Research 71, 1263–1271.
- Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., Benci, J.L., Xu, B., Dada, H., Odorizzi, P.M., Herati, R.S., Mansfield, K.D., Patsch, D., Amaravadi, 1113
 R.K., Schuchter, L.M., Ishwaran, H., Mick, R., Pryma, D.A., Xu, X., Feldman, M.D., Gangad 114
 har, T.C., Hahn, S.M., Wherry, E.J., Vonderheide, R.H., Minn, A.J., 2015. Radiation and dual 1115
 checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377.
- Vernuccio, S., Broadbelt, L.J., 2019. Discerning complex reaction networks using automated 1118 generators. AIChE Journal 65, e16663. 1119
- Wang, Z., Cao, S., Morris, J.S., Ahn, J., Liu, R., Tyekucheva, S., Gao, F., Li, B., Lu, W., Tang,
 X., Wistuba, I.I., Bowden, M., Mucci, L., Loda, M., Parmigiani, G., Holmes, C.C., Wang,
 W., 2018. Transcriptome Deconvolution of Heterogeneous Tumor Samples with Immune
 Infiltration. iScience 9, 451–460.
- Wells, A., Wiley, H.S., 2018. A systems perspective of heterocellular signaling. Essays Biochem. 62, 607–617.

1124

1125

1126

1127

1128

1129

- Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P., Levine, D., Carter, S.L., Getz, G., Stemke-hale, K., Mills, G.B., Verhaak, R., 2013. Inferring tumour purity and stromal and immune cell admixture from expression data. Nature Communications 4, 2612.
- Zaitsev, K., Bambouskova, M., Swain, A., Artyomov, M., 2019. Complete deconvolution of cellular mixtures based on linearity of transcriptional signatures. Nature communications 10, 2209. 1131
- Zhou, X., Franklin, R.A., Adler, M., Jacox, J.B., Bailis, W., Shyer, J.A., Flavell, R.A., Mayo, A.,
 Alon, U., Medzhitov, R., 2018. Circuit Design Features of a Stable Two-Cell System. Cell
 1132, 744–757.
- Zou, M., Conzen, S.D., 2005. A new dynamic bayesian network (DBN) approach for identifying gene regulatory networks from time course microarray data. Bioinformatics 21, 71–79. 1136

Figure Legends

Figure 1 - A computational workflow combines digital cytometry with Bayesian network inference to estimate how a genetic 1138 driver impacts the heterocellular network within a tissue. Digital cytometry deconvolutes a bulk transcriptomic profile using gene 1139 signatures that correspond to different stromal, malignant, and immune cell types. The results estimate the prevalence of the different 1140 cell types within the tissue sample, that is digital cytometry features. By using bulk transcriptomic profiles of defined patient populations, 1141 underlying variation in the inferred cellular composition coupled with changes in expression of a putative gene driver can be used to estimate 1142 how the heterocellular network is impacted by a gene driver using Bayesian Network inference. To illustrate the approach, we focused on 1143 CCN4 as a gene driver. The resulting directed acyclic graphs represent the collective conditional independence among modeled nodes of the 1144 network. 1145

Figure 2 - Summary of the evidence obtained from the TCGA breast cancer dataset supporting the consensus edges in the seed network. Edges ordered based on the number of algorithms that detected that an edge was enriched (bar graph - left axis) and the strength of enrichment (dotted lines - right axis). The lines associated with the strength of enrichment represent the minimum (dashed line) and maximum (dotted line) values obtained by the different algorithms. Coloring of bar graph indicates whether a clear direction was associated with an edge (green), an edge was significantly enriched but without a clear direction (yellow), or that an edge was excluded from the consensus seed network list (tan).

Figure 3 - A directed acyclic graph (DAG) representing the conditional probability distribution inferred using the digital cy-1152 tometry features extracted from the breast cancer arm of the TCGA. The nodes of the graph represent features, such as CCN4 gene 1153 expression (rectangle), sample attribute (hexagon), or the prevalence of a particular cell type/state (oval). The edges represent inferred causal 1154 relationships among the nodes. The black lines with arrow heads represent a positive causal relation while red lines with horizontal bars 1155 represent a negative or inhibitory causal relation, where the extent of influence of the parental node is annotated by the number beside the 1156 edge. The number included within the node symbol represents the average normalized value of the digital cytometry feature within the dataset 1157 with values of all of the parental nodes set to zero. The width of the edge is proportional to the posterior probability of inclusion into the 1158 DAG. 1159

Figure 4 - Conditional probability query of the BRCA DAG compared against digital cytometry estimates obtained from experimental data. Experimental samples obtained from normal mammary and tumor tissue are shown as filled versus open circles, respectively. Samples of the conditional probability model for p(Cancer < 0.15) (orange) and p(Cancer > 0.85) (blue) for CD8 T cells (A), CD4 T cells (B), active NK cells (C), B cells (D), Macrophages (E) and Cancer Associated Fibroblasts (F). Linear trendlines are superimposed on the conditional probability samples.

Figure 5 - Two DAGs representing the conditional probability distributions inferred using the digital cytometry features extracted from the two melanoma-related datasets. (A) Analysis of a bulk RNAseq dataset obtained from patients with common pigmented nevi and primary melanoma ($n_{samples} = 78$). (B) Analysis of primary melanoma samples extracted from the SKCM arm of the TCGA ($n_{samples} = 94$). The DAGs are summarized using similar notation as described in Figure 3. Dotted lines indicate edges that were included in the consensus seed network but, as the samples were all from patients with cancer, had no evidence in the TCGA dataset.

Figure 6 - CCN4 knock-out in two syngeneic mouse models of melanoma induces a similar shift in NK cells and T and B 1170 lymphocytes as observed in human breast cancer and melanoma. (A) The percentage of live CD45+ cells isolated from tumors 1171 generated by inoculating s.c. with wt (red) and CCN4 KO (blue) variants of B16F0 (o and x's) and YUMM1.7 (\Box and +'s) cells, where the 1172 log-linear trends are highlighted by dotted lines. CD45+ values were obtained from three different antibody panels that quantified T cells, 1173 B/NK cells, and myeloid cells in TIL isolates from each mouse (n = 3 for YUMM1.7 and n = 4 for B16F0 variants). (B) A comparison of 1174 the ratio of NK cells (black), CD8+ T cells (red), CD4+ T cells (blue), and B cells (green) to live CD45+ TILs in s.c. tumors generated using 1175 wt B16F0 and YUMM1.7 cells. (C) Comparing the log ratio in prevalence of the different cell types when CCN4 is present (WT) versus 1176 absent (CCN4 KO) predicted by the BRCA (1st column) and SKCM (4th column) DAGs and observed experimentally using the B16F0 (2nd 1177 column) and YUMM1.7 (3rd column) mouse models. Median results for NK cells (black), CD8+ T cells (red), CD4+ T cells (blue), and B 1178 cells (green) in the different settings are connected by lines. (D) TIL comparison upon CCN4 KO in B16F0 and YUMM1.7 mouse models 1179 stratified by NK cells, CD8+ T cells, CD4+ T cells, and B cells (top to bottom). p-values calculated between wt and CCN4 KO pairs using 1180 Student's t-test. 1181

Figure 7 - Myeloid immune cell subsets differentially infiltrate tumors derived from wt B16F0 and YUMM1.7 cells but shift in 1182 similar ways upon CCN4 knock-out. (A) A comparison of the ratio of CD11c- (black) and CD11c+ (gray) macrophages, CD11c+ Mo-1183 MDSC (green), Mo-MDSC (blue), and PMN-MDSC (red) to live CD45+ TILs in s.c. tumors generated using wt B16F0 and YUMM1.7 cells. 1184 (B) Comparing the log ratio in prevalence of the different myeloid cell types when CCN4 is present (WT) versus absent (CCN4 KO) predicted 1185 by the BRCA (1st column) and SKCM (4th column) DAGs and observed experimentally using the B16F0 (2nd column) and YUMM1.7 (3rd 1186 column) mouse models. Macrophages are the only myeloid cell subset inferred from the BRCA and SKCM datasets and are assumed to be 1187 related to CD11c- macrophages in mouse models. Median results in the different settings are connected by lines. (C and D) A representative 1188 scatter plot of GR1 versus CD11c expression in gated live CD45+ CD11b+ TILs obtained from wt (C) and CCN4 KO (D) YUMM1.7 tumors. 1189 The right panel shows MHCII versus F4/80 expression in the GR1⁺ CD11c⁻ subset. (E) TIL comparison upon CCN4 KO in B16F0 and 1190 YUMM1.7 mouse models stratified by myeloid cell subsets (top to bottom). p-values calculated between wt and CCN4 KO pairs using 1191 Student's t-test. 1192

1137

Figure 8 - CCN4 has no direct effect on T cell proliferation but impairs CD8⁺ T cell function. The distribution in cell trace staining 1193 among live CD4⁺ (A) and CD8⁺ (B) T cells stimulated with α CD3/ α CD28 (AP beads) alone or in the presence of media conditioned by 1194 wt B16F0 cells (AP beads + WT TCM), media conditioned by CCN4 KO B16F0 cells (AP beads + CCN4 KO TCM), or with 10 ng/ml of 1195 recombinant mouse CCN4 (AP beads + rCCN4). The distribution in the corresponding unstimulated cells (gray) are shown at the bottom. 1196 1197 The colored vertical lines indicate the predicted dilution of cell trace staining in each generation based on the unstimulated controls. (C) CD8+ T cells isolated from the spleens of C57BL/6 mice that rejected YUMM1.7 tumors were cultured in an in vitro ELISPOT assay using 1198 variants of the YUMM1.7 cell line as targets (wt YUMM1.7 - yellow, CCN4 KO YUMM1.7 - light green, CCN4 KO YUMM1.7 with a blank 1199 inducible expression vector - dark green and blue, CCN4 KO YUMM1.7 with a CCN4 inducible expression vector - purple and red). Variants 1200 containing the inducible expression vector were also cultured in the absence (dark green and purple) or presence of doxycycline (blue and 1201 red). CD8+ T cells expressing IFN γ and TNF α were quantified following 24 hour co-culture (bar graph). Statistical significant between 1202 pairs was assessed using a Student's t-test, where * = p-value < 0.05 and *** = p-value < 0.001. 1203




Fig. 1. A computational workflow combines digital cytometry with Bayesian network inference to estimate how a genetic driver impacts the heterocellular network within a tissue.




Fig. 2. Summary of the evidence obtained from the TCGA breast cancer dataset supporting the consensus edges in the seed network.




Fig. 3. A directed acyclic graph (DAG) representing the conditional probability distribution inferred using the digital cytometry features extracted from the breast cancer arm of the TCGA.




Fig. 4. Conditional probability query of the BRCA DAG compared against digital cytometry estimates obtained from experimental data.




Fig. 5. A DAG representing the conditional probability distribution inferred using the digital cytometry features extracted from the two melanoma-related datasets.




Fig. 6. CCN4 knock-out in two syngeneic mouse models of melanoma induces a similar shift in NK cells and T and B lymphocytes as observed in human breast cancer and melanoma.




Fig. 7. Myeloid immune cell subsets differentially infiltrate tumors derived from wt B16F0 and YUMM1.7 cells but shift in similar ways upon CCN4 knock-out.




Fig. 8. CCN4 has no direct effect on T cell proliferation but impairs CD8⁺ T cell function.

Table S1. List of edges, whether an edge was predicted to promote or inhibit the target node, and the strength inferred using the different structure learning algorithms in analyzing the features present in TCGA breast cancer dataset. Rows highlighted in green were included in the consensus seed network, yellow indicate that the directionality was unclear, and red indicate edges included in the "blacklist". The edge numbers correspond to the x-axis in Figure 2.

Edge No 1	from CCN4	to Mesenchymal		aracne CorSign +	CorSign	iamb strength 2.02E-138	iamb CorSign +	iamb.fdr strength 2.02E-138	CorSign	tabu strength 1.95E-148		mmhc strength 1.79E-139		hc strength 1.95E-148	hc CorSign +	pc_stable strength 1.79E-139	CorSign	Hit Number 9 9	Min strength 1.95E-148	
2	pM0 pM1	pM1 pM0	-	-	-	0.00E+00		0.00E+00		3.77E-48		0.00E+00		3.77E-48	-	0.00E+00		9	0.00E+00	3.77E-48
3	pM0 pM2	pM2 pM0			-	0.00E+00		0.00E+00		0.00E+00		0.00E+00		0.00E+00		0.00E+00		9	0.00E+00	0.00E+00
4	CAF_lg Mesenchymal	Mesenchymal CAF_lg	+ +	+	+ +	9.62E-73	+	9.62E-73	+	2.94E-97	+	2.35E-86	+	2.94E-97	+	8.08E-86		9 9		9.62E-73
5	Cancer CCN4	CCN4 Cancer	+	+	+	2.06E-55	+	2.06E-55	+	2.06E-55	+	2.06E-55	+	2.06E-55	+	2.06E-55		9 9		2.06E-55
6 6	NK.cells.active_lg NK.cells.rest_lg	NK.cells.rest_lg NK.cells.active_lg			-	4.80E-30	•	4.80E-30		1.15E-33		4.80E-30		1.15E-33	•	4.80E-30		9 9		4.80E-30
7	B.cells.ive_lg T.cells.CD8_lg	T.cells.CD8_lg B.cells.ive_lg	+ +	+	+	9.25E-27	+	2.92E-27	+	3.10E-16		2.92E-27		3.10E-16	+	2.92E-27		9		3.10E-16
8	Cancer Epithelial	Epithelial Cancer				1.66E-25		1.66E-25		1.66E-25		1.66E-25		1.66E-25	•	2.23E-22		9		2.23E-22
9 9 10	CAF_lg proliferation Endothelial.cells_lg	proliferation CAF_lg proliferation		-		6.37E-21	-	6.37E-21		3.37E-12 5.75E-10		7.01E-20		3.37E-12 5.75E-10	÷	1.80E-18		9 9 9		3.37E-12 5.75E-10
10	proliferation	Endothelial.cells_lg				2.88E-15		2.88E-15		5.752-10		2.88E-15	1.1	5.752-10		6.23E-18		9		2.01E-13
	Macrophages_sc_lg pM1	CD4Tcell_sc_lg T.cells.CD8_lg	+++	+++++++++++++++++++++++++++++++++++++++	+ +	1.91E-16 8.18E-13	+++++++++++++++++++++++++++++++++++++++	5.09E-16 3.53E-14	+++++	3.07E-14 8.98E-15	+++	5.09E-16 3.53E-14		3.07E-14 8.98E-15	+ +	2.01E-13 3.53E-14		9		8.18E-13
12	T.cells.CD8_lg Macrophages_sc_lg	pM1	+ +	+ +	+ +	9.15E-13	+	2.38E-12	+	6.56E-12	+	2.38E-12		6.56E-12	+	2.38E-12		9		6.56E-12
13	T.cells.CD8_lg CAF_lg	Macrophages_sc_lg T.cells.CD8_lg	+	+	+	2.84E-07		3.06E-07		3.42E-09		3.06E-07		3.42E-09		3.06E-07		9 9	3.42E-09	3.06E-07
14 15	T.cells.CD8_lg Cancer	CAF_lg proliferation	+	-	+	6.68E-23	+	6.68E-23	+	4.70E-12	+	3.72E-10	+	4.70E-12	+	1.93E-08	+	9 8	6.68E-23	1.93E-08
15 16	proliferation Cancer	Cancer Endothelial.cells_lg	+		+	7.40E-09		7.40E-09		3.67E-38		7.40E-09		3.67E-38		2.10E-05		8 8	3.67E-38	2.10E-05
16 17	Endothelial.cells_lg CD4Tcell_sc_lg	Cancer Endothelial.cells_lg	÷		÷													8	3.64E-10	7.84E-07
18	Endothelial.cells_lg B.cells.ive_lg	CD4Tcell_sc_lg CD4Tcell_sc_lg	+ +		+ +	5.65E-08 2.95E-06	+++++++++++++++++++++++++++++++++++++++	2.93E-07 1.95E-06	+ +	3.64E-10 2.17E-07		2.93E-07 1.95E-06		3.64E-10 2.17E-07	+ +	7.84E-07 7.31E-05		8	2.17E-07	7.31E-05
	CD4Tcell_sc_lg Cancer	B.cells.ive_lg pM2	+		+					7.00E-04		1.91E-42		7.00E-04		1.91E-42		8 7 7	1.91E-42	7.00E-04
	B.cells.ive_lg Endothelial.cells_lg	Endothelial.cells_lg	+	t	+	2.71E-22		2.71E-22				1.52E-18				4.01E-20	+	7	2.71E-22	1.52E-18
21	pM2 proliferation	B.cells.ive_lg proliferation pM2				2./16-22	•	2.710-22		1.02E-10	•	2.09E-11		1.02E-10	-	3.30E-10		7	2.09E-11	3.30E-10
	Epithelial	Neutrophils_lg			-	2.82E-03				1.62E-03		6.79E-04		1.62E-03		6.79E-04		, 7 7	6.79E-04	2.82E-03
	CAF_lg pM1	pM1 CAF_lg			-					4.37E-12		3.74E-24		4.37E-12		1.06E-21		6 6	3.74E-24	4.37E-12
	Cancer Mesenchymal	Mesenchymal Cancer	+		+					8.89E-17	+	1.16E-16	+	8.89E-17	+	1.16E-16	+	6 6	8.89E-17	1.16E-16
	Neutrophils_lg pM2	pM2 Neutrophils_lg	+		+ +					7.51E-09	+	1.57E-04	+	7.51E-09	+	1.57E-04		6 6		1.57E-04
26	Neutrophils_lg	Macrophages_sc_lg	+		+	1.59E-03	+					1.86E-03	+			1.86E-03	+	5 5		1.86E-03
27	pM1 pM2	pM2 pM1				3.43E-04		3.43E-04		0.00E+00				0.00E+00				4		3.43E-04
28	NK.cells.rest_lg T.cells.CD8_lg NK cells cells	T.cells.CD8_lg NK.cells.rest_lg				1.24E-02				7.88E-04				7.88E-04				3		1.24E-02
29	NK.cells.active_lg CD4Tcell_sc_lg B.cells.ive_lg	CD4Tcell_sc_lg NK.cells.active_lg Epithelial	+			1.26E-03				1.08E-03				1.08E-03		1.73E-03	+	3 3 3		1.26E-03 8.19E-03
	Epithelial	B.cells.ive_lg	+									8.19E-03	+			1.732-03		3		1.23E-02
31	pM1 Cancer	CD4Tcell_sc_lg pM1	+		+					2.35E-35	+			2.35E-35	+	1.23E-02	+	3		2.35E-35
32	pM1 Cancer	Cancer pM0								5.03E-25				5.03E-25				2 2		5.03E-25
33	pM0 Mesenchymal	Cancer Endothelial.cells_lg								4.02E-19				4.02E-19	+			2 2	4.02E-19	4.02E-19
34 35	Endothelial.cells_lg B.cells.ive_lg	Mesenchymal pM1								4.18E-19	+			4.18E-19	+			2 2	4.18E-19	4.18E-19
35 36	pM1 Macrophages_sc_lg	B.cells.ive_lg CAF_lg								5.33E-17				5.33E-17	-			2	5.33E-17	5.33E-17
36 37	CAF_lg Cancer	Macrophages_sc_lg B.cells.ive_lg								3.36E-13				4.79E-07				2	3.36E-13	4.79E-07
38	B.cells.ive_lg pM0 Mesenchymal	Cancer Mesenchymal pM0								1.51E-12	+			1.51E-12	+			2	1.51E-12	1.51E-12
39 39	pM1 Endothelial.cells_lg	Endothelial.cells_lg pM1								4.23E-12	+			4.23E-12	+			2	4.23E-12	4.23E-12
	CCN4	proliferation								7.29E-12				7.29E-12				2	7.29E-12	7.29E-12
41	Cancer T.cells.CD8 lg	T.cells.CD8_lg Cancer								2.30E-10				2.30E-10				2	2.30E-10	2.30E-10
42 42	Macrophages_sc_lg pM0	pM0 Macrophages_sc_lg								2.14E-08	•			2.14E-08	-			2 2		2.14E-08
43 43	NK.cells.rest_lg pM0	pM0 NK.cells.rest_lg								2.12E-07	+			2.12E-07	+			2 2		2.12E-07
- 44	Mesenchymal Neutrophils_lg	Neutrophils_lg Mesenchymal								2.39E-07				2.39E-07	+			2 2		2.39E-07
45	CCN4 Macrophages_sc_lg	Macrophages_sc_lg CCN4								4.84E-07				4.84E-07				2 2		4.84E-07
46	Cancer NK.cells.rest_lg	NK.cells.rest_lg								4.25E-06				4.25E-06				2		4.25E-06
47	Epithelial CD4Tcell_sc_lg B.cells.ive_lg	CD4Tcell_sc_lg Epithelial NK colls rest_lg								9.98E-06				9.98E-06				2 2 2		9.98E-06
48 48 49	B.cells.ive_lg NK.cells.rest_lg Epithelial	NK.cells.rest_lg B.cells.ive_lg Mesenchymal								3.72E-05 7.35E-05				3.72E-05 7.35E-05	•			2 2 2		3.72E-05 7.35E-05
49	Mesenchymal Endothelial.cells_lg	Epithelial								7.61E-05				7.61E-05				2 2 2		7.61E-05
50 51	Neutrophils_lg	Endothelial.cells_lg								3.71E-04				3.71E-04	+			2		3.71E-04
51 52	CAF_lg Mesenchymal	pM2 T.cells.CD8_lg								2.04E-04				2.04E-04	+			2		2.04E-04
52	T.cells.CD8_lg CCN4	Mesenchymal NK.cells.active_lg								2.64E-04				2.64E-04				2 2		2.64E-04
53 54	NK.cells.active_lg B.cells.ive_lg	CCN4 CAF_lg								1.48E-03				1.48E-03				2 2		1.48E-03
54 55	CAF_lg Epithelial	B.cells.ive_lg CAF_lg								2.94E-03				2.94E-03	+			2 2		2.94E-03
55 56	CAF_lg NK.cells.rest_lg	Epithelial proliferation								2.80E-02	+			2.80E-02	+			2 2	2.80E-02	2.80E-02
56 57	proliferation Macrophages_sc_lg	NK.cells.rest_lg proliferation								1.53E-01				1.53E-01	-			2	1.53E-01	1.53E-01
57 58	proliferation CCN4	Macrophages_sc_lg B.cells.ive_lg								5.87E-08	÷							2	5.87E-08	5.87E-08
- 58	B.cells.ive_ig	CCN4																1		

Table S2. List of edges, whether an edge was predicted to promote or inhibit the target node, and the strength inferred using the different structure learning algorithms in analyzing the features present in dataset comprised of common melanocytic nevi and primary melanoma tissue samples (GEO). Rows highlighted in green were included in the consensus seed network, yellow indicate that the directionality was unclear, and red indicate edges included in the "blacklist". The edge numbers correspond to the x-axis in Figure 4A.

Edge No	from	to		aracne CorSign		iamb strength	iamb CorSign	iamb.fdr strength		tabu strength	tabu CorSign	mmhc strength	mmhc CorSign	hc strength	hc CorSign	pc_stable strength	pc_stable CorSign	Hit Number	Min strength	Max strength
1	pM1	pM2	-	-	-	2.40E-41	-	2.40E-41	-	2.40E-41	-	2.40E-41	-	2.40E-41	-	2.40E-41	-	9	2.40E-41	2.40E-41
1	pM2 pM0	pM1 pM2	-		-	3.31E-38	-	3.31E-38	-	3.31E-38	-	3.31E-38	-	3.31E-38	-	3.31E-38	-	9	3.31E-38	3.31E-38
2	pM2	pM0	-	•	-													9		
3	Cancer	Mesenchymal Cancer	+	+	+	6.29E-09	+	2.09E-18	+	8.02E-13	+	6.29E-09	+	8.02E-13	+	2.46E-12	+	9	2.09E-18	6.29E-09
	Cancer	Epithelial	-	-	-	4.24E-15	-	4.24E-15	-	4.24E-15	-	4.24E-15	-	2.79E-16	-	4.24E-15	-	9	2.79E-16	4.24E-15
4 5	Epithelial CAF_lg	Cancer Mesenchymal	+	+	+			6.70E-15	+							2.20E-12	+	9	6 70F-15	5.98E-05
5	Mesenchymal	CAF_lg	+	+	+	2.75E-14	+	0.702 15	1	7.46E-12	+	2.75E-14	+	5.98E-05	+	2.201 12		9	0.702 15	5.56E 05
6	Macrophages_sc_lg T.cells.CD8 lg	T.cells.CD8_lg Macrophages sc lg	+	+	+	9.32E-06	+	1.82E-11	+	7.68E-06	+	1.79E-04	+	7.68E-06	+	1.79E-04	+	9	1.82E-11	1.79E-04
7	NK.cells.active_lg	NK.cells.rest_lg	-	-	-							1.02E-06	-					9	1.01E-09	1.68E-05
7	NK.cells.rest_lg	NK.cells.active_lg	-	-	-	1.01E-09	-	1.68E-05	-	1.01E-09	-			1.01E-09	-	1.68E-05	-	9	8 60E 08	4.15E-07
8	Endothelial.cells_lg	CD4Tcell_sc_lg	+	+	+	4.15E-07	+	8.60E-08	+	4.15E-07	+	4.15E-07	+	4.15E-07	+	4.15E-07	+	9	8.00L-08	4.152-07
9	CCN4 Mesenchymal	Mesenchymal	+	+	+	6.48E-05	+			8.38E-07	+	6.48E-05	+	8.38E-07	+	2.29E-02	+	8	8.38E-07	2.29E-02
-	NK.cells.active_lg	T.cells.CD8_lg	+	+	+	1.05E-04	+			1.19E-03	+	3.93E-03	+	1.19E-03	+	3.93E-03	+	8	1.05E-04	3.93E-03
10 11	T.cells.CD8_lg	NK.cells.active_lg	+	+	+													8	4 505 61	4 505 6 *
11	CD4Tcell_sc_lg Macrophages_sc_lg	Macrophages_sc_lg CD4Tcell_sc_lg	+	+	+	4.58E-04	+			4.58E-04	+	4.58E-04	+	4.58E-04	+	4.58E-04	+	8	4.58E-04	4.58E-04
12	NK.cells.rest_lg	pM0	+	+	+					2.22E-04	+			2.22E-04	+	1.17E-03	+	7	6.30E-05	1.17E-03
12 13	pM0 pM1	NK.cells.rest_lg T.cells.CD8_lg	+	+ +	+					5.96E-03	+	6.30E-05 3.70E-03		5.96E-03	+	3.70E-03	+	7	3.70F-03	5.96E-03
13	T.cells.CD8_lg	pM1	+	+	+													7		
14	Cancer NK.cells.active_lg	NK.cells.active_lg Cancer		+		8.85E-16	+			8.85E-16	+			8.85E-16	+			4	8.85E-16	8.85E-16
15	CAF_lg	Endothelial.cells_lg		+												3.11E-06	+	4	3.11E-06	8.04E-04
15	Endothelial.cells_lg Cancer	CAF_lg proliferation		+		1.47E-09				8.04E-04 6.39E-11	+			4.19E-04 6.39E-11	+			4 3	6 20E 11	1.47E-09
16	proliferation	Cancer				1.472-05	Ŧ			0.391-11	-			0.351-11	-			3	0.391-11	1.471-03
17 17	Macrophages_sc_lg	Mesenchymal		+						7.24E-09				7.24E-09				3 3	7.24E-09	7.24E-09
17	Mesenchymal Endothelial.cells_lg	Macrophages_sc_lg pM0		+						7.24E-09	+			7.24E-09	+			3	1.27E-04	1.27E-04
18	pM0	Endothelial.cells_lg		-	-					1.27E-04	-							3		
19 19	B.cells.naive_lg Endothelial.cells lg	Endothelial.cells_lg B.cells.naive_lg		+						3.41E-03	+			3.41E-03	+			3 3	3.41E-03	3.41E-03
20	Cancer	CCN4								5.06E-11	+			5.06E-11	+			2	5.06E-11	5.06E-11
20 21	CCN4 Endothelial.cells lg	Cancer Mesenchymal								2.75E-10	+			2.75E-10	+			2	2.75E-10	2.75E-10
21	Mesenchymal	Endothelial.cells_lg																2		
22 22	Macrophages_sc_lg pM1	pM1 Macrophages_sc_lg								5.29E-07	+			5.29E-07	+			2 2	5.29E-07	5.29E-07
23	Epithelial	pM0								3.92E-05	-			3.92E-05	-			2	3.92E-05	3.92E-05
23 24	pM0 Endothelial.cells_lg	Epithelial proliferation								5.19E-05				5.19E-05				2 2	5 105 05	5.19E-05
24	proliferation	Endothelial.cells_lg								5.152-05	•				•			2	J.1JL-03	J.1JL-03
25	CCN4 Neutrophils lg	Neutrophils_lg CCN4	_	_	_		_		_	7.22E-04	+	_		7.22E-04	+	_	_	2	7.22E-04	7.22E-04
25	CAF_lg	T.cells.CD8_lg								8.87E-03	+			8.87E-03	+			2	8.87E-03	8.87E-03
26	T.cells.CD8_lg	CAF_lg																2	2.005.05	2 005 05
27 27	Macrophages_sc_lg NK.cells.rest_lg	NK.cells.rest_lg Macrophages_sc_lg								2.08E-02	-			2.08E-02	-			2 2	2.08E-02	2.08E-02
28	pM0	pM1								2.28E-02	-			2.28E-02	-			2	2.28E-02	2.28E-02
28 29	pM1 Endothelial.cells_lg	pM0 Epithelial												9.69E-04	+			2 1	9.69E-04	9.69E-04
29	Epithelial	Endothelial.cells_lg																1		
30 30	CAF_lg CCN4	CCN4 CAF_lg												2.35E-01	+			1	2.35E-01	2.35E-01
31	Cancer	pM2		-										2.552 01	•			1	1.00E+00	1.00E+00
31	pM2	Cancer		-														1		

Table S3. List of edges, whether an edge was predicted to promote or inhibit the target node, and the strength inferred using the different structure learning algorithms in analyzing the features present in primary melanoma tissue samples in the TCGA SKCM dataset. Rows highlighted in green were included in the consensus seed network, yellow indicate that the directionality was unclear, and red indicate edges included in the "blacklist". The edge numbers correspond to the x-axis in Figure 4B.

Edge No	from	to	mmpc CorSign	aracne CorSign	hiton CorSign	iamb strength	iamb CorSign	iamb.fdr strength		tabu strength	tabu CorSign	mmhc strength	mmhc CorSign		hc CorSign	pc_stable strength	pc_stable CorSign	Number		Max strength
1	pM0	pM2	-	-	-					6.36E-46	-	2.04E-18	-	6.36E-46	-			9	6.36E-46	2.04E-18
1	pM2	pM0	-	-	-	6.36E-46	-	6.36E-46	-							6.36E-46	-	9		
2	pM0	pM1	-	-	-					9.96E-07	-	9.96E-07	-	9.96E-07	-			9	1.59E-34	9.96E-07
2	pM1	pM0		1.1		1.59E-34	-	1.59E-34	-	5 205 44				2.205.40		1.59E-34	-	9	2 265 40	5 205 44
3	CAF_lg	Mesenchymal	+	+	++	3.26E-18	+	3.26E-18	+	5.38E-14	+	3.26E-18	+	3.26E-18	+	3.26E-18	+	9 9	3.26E-18	5.38E-14
2 2	Mesenchymal CAF Ig	CAF_lg Macrophages sc lg	+	+	+	1.45E-08	+	1.45E-08		8.38E-11	+	1.45E-08	+	1.02E-11	+	1.45E-08		9	1 025 11	1.45E-08
4	Macrophages_sc_lg		+	+	+	1.450-08	+	1.456-06	+	0.305-11	+	1.450-06	+	1.026-11	+	1.45E-06	+	9	1.026-11	1.45E-06
5	Macrophages_sc_lg		+	+	+	1.43E-07	+	1.43E-07	+	1.23E-11	+	1.43E-07	+	1.23E-11	+	1.43E-07	+	9	1 225 11	1.43E-07
5	T.cells.CD8 lg	Macrophages sc lg	+			1.431-07	Ŧ	1.431-07	Ŧ	1.251-11	+	1.431-07	Ŧ	1.251-11	-	1.431-07	+	9	1.251-11	1.431-07
6		NK.cells.rest lg								2.37E-09				2.37E-09		2.37E-09		9	2 01F-10	2.37E-09
6	NK.cells.rest_lg	NK.cells.active_lg	-			2.01E-10	_	2.01E-10		2.572.05		2.01E-10		2.572.05		2.572 05		9	2.012 10	2.572 05
7	Endothelial.cells Ig		+	+	+											1.28E-07	+	8	3.73F-08	1.28E-07
7	Mesenchymal	Endothelial.cells lg	+	+	+	3.73E-08	+			3.73E-08	+	3.73E-08	+	3.73E-08	+			8		
8	CD4Tcell sc lg	Macrophages sc lg	_	-	-													8	1.96E-06	2.61E-04
8	Macrophages sc lg	CD4Tcell sc lg	-	-	-	2.61E-04	-			1.96E-06	-	2.61E-04	-	1.96E-06	-	2.61E-04	-	8		
9	CCN4	NK.cells.rest_lg	+	+	+	1.32E-03	+			1.57E-02	+	1.32E-03	+	1.57E-02	+	1.57E-02	+	8	1.32E-03	1.57E-02
9	NK.cells.rest_lg	CCN4	+	+	+													8		
10	CCN4	Mesenchymal	+	+	+	1.14E-06	+			2.38E-02	+					3.83E-06	+	6	1.14E-06	2.38E-02
10	Mesenchymal	CCN4	+	+	+													6		
11	NK.cells.active_lg	pM0		-						3.16E-05	-			3.16E-05	-			3	3.16E-05	3.16E-05
11	pM0	NK.cells.active_lg		-														3		
12	Macrophages_sc_lg	proliferation		-						1.72E-04	-			1.72E-04	-			3	1.72E-04	1.72E-04
12	proliferation	Macrophages_sc_lg		-														3		
13	Endothelial.cells_lg			+						1.01E-02	+			1.01E-02	+			3	1.01E-02	1.01E-02
13	Epithelial	Endothelial.cells_lg		+														3		
14		Epithelial		+														3	1.36E-02	1.36E-02
14	Epithelial	CD4Tcell_sc_lg		+						1.36E-02	+			1.36E-02	+			3		
15	pM1	pM2								9.70E-30	-			9.70E-30	-			2	9.70E-30	9.70E-30
15	pM2	pM1																2		
16	Macrophages_sc_lg									2 545 00				4 205 04				2	2.51E-06	1.29E-04
17	NK.cells.active_lg	Macrophages_sc_lg CCN4								2.51E-06	+			1.29E-04	+			2	4 755 00	4 755 00
	CAF_Ig CCN4	CAF_lg								4.75E-06	+			4.75E-06	+			2	4.75E-06	4.75E-06
	CAF_lg	T.cells.CD8_lg								4.75E-06 1.58E-05	+			4.75E-06 1.58E-05	+			2	1 595 05	1.58E-05
	T.cells.CD8 lg	CAF Ig								1.565-05	-			1.565-05	-			2	1.565-05	1.365-03
	CAF Ig	CD4Tcell sc lg								5.54E-03	+			5.54E-03	+			2	5 54F-03	5.54E-03
19		CAF Ig								5.542 05				5.542 05				2	J.J4L 0J	5.542 05
	Macrophages sc lg																	1	1.64F-02	1.64E-02
20	pM1	Macrophages_sc_lg												1.64E-02	+			1	2.012.02	
	B.cells.naive_lg	T.cells.CD8_lg		+										2.2.12.02				1	1.00E+00	1.00E+00
21	T.cells.CD8 lg	B.cells.naive Ig		+								_	_			_		1		
22		T.cells.CD8_lg		+														1	1.00E+00	1.00E+00
	T.cells.CD8_lg	NK.cells.active_lg	_	+	_		_	_	_		_				_			1		
																			•	

Table S4. Proliferation metrics associated CD4⁺ and CD8⁺ T cells stimulated in vitro in different conditions. Dil: fraction diluted; PF: Precursor frequency, %dividing cells; PI: Proliferation index; and SD^D: proliferation variance. Summary statistics were calculated from three biological replicates and represented as mean (standard deviation). Statistical significance was assessed using type III repeated measures ANOVA, where * indicates a p-value < 0.05.

		Live CD4	+ T cells		Live CD8+ T cells						
Experimental Conditions	Dil	PF	PI	SD ^D	Dil	PF	PI	SD₽			
AP beads + rCCN4	0.670 (0.012)	0.392 (0.014)	1.407 (0.033)	0.274	0.983 (0.003)	0.851 (0.014)	2.655 (0.045)	0.103			
AP beads + CCN4 KO TCM	0.472* (0.008)	0.221* (0.003)	1.404 (0.023)	0.274	0.914* (0.015)	0.715* (0.032)	1.729* (0.044)	0.205			
AP beads + WT TCM	0.552* (0.047)	0.282* (0.038)	1.403 (0.031)	0.272	0.920* (0.020)	0.704* (0.044)	1.923* (0.052)	0.189			
AP beads	0.655 (0.043)	0.366 (0.035)	1.473 (0.060)	0.255	0.982 (0.002)	0.841 (0.026)	2.756 (0.187)	0.106			
No stimulation	0.046 (0.025)	0.016 (0.013)	1.763 (1.056)	0.371	0.062 (0.018)	0.008 (0.004)	2.520 (0.441)	0.229			

NA - ul · - u	Classe	Elson and a sec	Manual fractions of
Marker	Clone	Fluorophore	Manufacturer
LIVE/DEAD Fix		Violet/Pacific Blue	Invitrogen
CD45	30-F11	BB515	BD Biosciences #564590
CD3e	500A2	Alexa Fluor 700	BioLegend #152316
CD4	GK1.5	APC-Cy7	BD Biosciences #552051
CD8a	REA601	APC	Miltenyi 130-109-248
CD161 (NK-1.1)	PK136	APC-Cy7	BioLegend #108723
CD45R/B220	RA3-6B2	APC	BioLegend #103212
CD49b	DX5	PerCP/Cy5.5	Biolegend #108915
CD11b	M1/70	PerCP/Cy5.5	eBioscience #45-0112-80
CD11c	N418	PE	eBioscience #12-0114-81
F4/80	BM8	APC-Cy7	BioLegend #123117
Ly-6G/Ly-6C (Gr-1)	RB6-8C5	APC	BioLegend #108412
CD279 (PD-1)	REA802	PE	BioLegend #135205
I-A/I-E (MHC-II)	M5/114.15.2	Alexa Fluor 700	BioLegend #107622

Table S5. List of fluorophore-conjugated antibodies using to quantify cell subsets by flow cytometry.




Fig. S1. Distribution of extracted features associated with the BRCA TCGA dataset. Figure represents a normalized histogram (bar graph) and distribution (red line) in log-transformed feature values. The panels from left to right, top to bottom are Cancer attribute, CD4 T cells, Neutrophils, Endothelial cells, Cancer associated fibroblasts (CAFs), CD8 T cells, active NK cells, resting NK cells, Macrophages, näive B cells, proliferation, epithelial cell state, mesenchymal cell state, CCN4 gene expression, $p(M\Phi 0)$, $p(M\Phi 1)$, and $p(M\Phi 2)$.




Fig. S2. Distribution of extracted features associated with the dataset containing common melanocytic nevi and primary melanoma tissue samples (GEO). Figure represents a normalized histogram (bar graph) and distribution (red line) in log-transformed feature values. The panels from left to right, top to bottom are Cancer attribute, CD4 T cells, Neutrophils, Endothelial cells, Cancer associated fibroblasts, CD8 T cells, active NK cells, resting NK cells, Macrophages, naïve B cells, proliferation, epithelial cell state, mesenchymal cell state, CCN4 gene expression, $p(M\Phi0)$, $p(M\Phi1)$, and $p(M\Phi2)$.




Fig. S3. Distribution of extracted features associated with primary melanoma samples in the TCGA SKCM dataset. Figure represents a normalized histogram (bar graph) and distribution (red line) in log-transformed feature values. The panels from left to right, top to bottom are Cancer attribute, CD4 T cells, Neutrophils, Endothelial cells, Cancer associated fibroblasts, CD8 T cells, active NK cells, resting NK cells, Macrophages, naïve B cells, proliferation, epithelial cell state, mesenchymal cell state, CCN4 gene expression, $p(M\Phi 0)$, $p(M\Phi 1)$, and $p(M\Phi 2)$.




Fig. S4. Summary of the evidence obtained from two melanoma datasets supporting the consensus edges in the seed network. Analysis of datasets containing samples from both common pigmented nevi and primary melanoma (A) and from only primary melanoma (B). Edges ordered based on the number of algorithms that detected that an edge was enriched (bar graph - left axis) and the strength of enrichment (dotted lines - right axis). The lines associated with the strength of enrichment represent the minimum (dashed line) and maximum (dotted line) values obtained by the different algorithms. Coloring of bar graph indicates whether a clear direction was associated with an edge in one dataset (green) and in both datasets (green/blue), an edge was significantly enriched but without a clear direction in one dataset (yellow) and in both datasets (green/yellow), or that an edge was excluded from the consensus seed network list (tan).

bioRxiv preprint doi: https://doi.org/10.1101/2020.05.04.077107; this version posted May 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




Figure S2B. Conditional probability query of the SKCM DAG compared against digital cytometry estimates obtained from experimental data. Experimental samples obtained from primary melanoma tissue are shown as open circles. Samples of the conditional probability model for p(Cancer > 0.85) (blue) for CDB T cells (A), CD4 T cells (B), Active NK cells (C), B cells (D), Macrophages (E) and Cancer Associated Fibroblasts (F). Linear superimosed on the conditional probability amples.

Fig. S5. Conditional probability query of the SKCM DAG compared against digital cytometry estimates obtained from experimental data. Experimental samples obtained from primary melanoma tissue are shown as open circles. Samples of the conditional probability model for p(Cancer > 0.85) (blue) for CD8 T cells (A), CD4 T cells (B), active NK cells (C), B cells (D), Macrophages (E) and Cancer Associated Fibroblasts (F). Linear trendlines are superimposed on the conditional probability samples.




Fig. S6. Flow cytometry gating strategy for T cells. CD45 staining versus side scatter area was used to gate for CD45+ cells. Live Dead Pacific Blue staining versus side scatter area was used to then gate for Live $CD45^+$ cells, which were then gated based on $CD3e^+$ expression. Live $CD45^+$ $CD3e^+$ cells were further subdivided into $CD8^+$ T cells (live $CD8^+$ $CD3e^+$ $CD45^+$ cells), CD4 T cells (live $CD4^+$ $CD3e^+$ $CD45^+$ cells), and double negative T cells (live $CD8^ CD4^ CD3e^+$ $CD45^+$ cells).




Fig. S7. Flow cytometry gating strategy for B, NK, and NKT cells. CD45 staining versus side scatter area was used to gate for CD45+ cells. Live Dead Pacific Blue staining versus side scatter area was used to gate for Live CD45⁺ cells, which were then subdivided into B cells (live NK1.1⁻ B220⁺ CD3⁻ CD45⁺ cells), NK cells (live NK1.1⁺ B220⁻ CD3⁻ CD45⁺ cells), and NKT cells (live NK1.1⁺ CD3e⁺ CD45⁺ cells).




Fig. S8. Flow cytometry gating strategy for Tumor associated neutrophils and myeloid cell subsets. CD45 staining versus side scatter area was used to gate for CD45⁺ cells. Live Dead Pacific Blue staining versus side scatter area was used to gate for Live CD45⁺ cells, which were then subdivided into subsets based on CD11b staining followed by Gr1 versus CD11c staining. From the CD11b⁺ gate, myeloid-derived suppressor cells (MDSC) (live Gr1⁺ CD11c⁻ CD11b⁺ CD45⁺ cells) were subdivided into PMN-MDSC (F4/80⁻ MHCII⁺) and Mo-MDSC (F4/80⁺ MHCII⁺). CD11c⁺ Mo-MDSC were also quantified as (live F4/80⁺ MHCII⁺) Gr1⁺ CD11c^{int} CD11b⁺ CD45⁺ cells). Also from the CD11b⁺ gate, macrophages (live Gr1⁻ F4/80⁺ CD11b⁺ CD45⁺ cells) were subdivided into tumor-associated CD11c⁺ (CD11c^{int/+} MHCII^{hi}) and CD11c⁻ (CD11c⁻ MHCII^{lo}) subsets. The CD11b⁻ subset included tumor-associated neutrophils (TAN) (Gr1⁺ CD11c⁻ MHCII^{hi} F4/80⁻) and lymphoid dendritic cells (Gr1⁻ CD11c⁺ FSC-A^{hi} MHCII^{lo} F4/80⁻).




Fig. S9. Control experiments related to ELISPOT assay using an inducible CCN4 YUMM1.7 cell line. (A) CCN4 secretion, measured with ELISA, from CCN4-inducible cells in conditioned media in the presence of absence of doxycycline. (B) ELISPOT for IFN γ release with different target cells and different amount of effector CD8⁺ T cells (In vivo activated CD8⁺ T cells against YUMM1.7 (Ym1.7)). (C) ELISPOT for IFN γ with CCN4-inducible cells as targets using in vivo activated CD8₊ T cell against YUMM1.7. Results shown as mean \pm S.D. for three biological replicates.